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1 Introduction 
Once viewed as an infrequent disease of young pigs, Glässer’s disease has emerged 
as a major pathogen affecting naïve swine herds. Haemophilus parasuis (HPS), the 
etiological agent of Glasser’s disease, causes characteristic fibrinopurulent 
polyserositis, arthritis and meningitis in swine (BLANCO et al., 2008). Present day 
production practices such as segregated early weaning, mixing swine from different 
herds, high-herd health status, and the isolated swine populations have increased 
the prevalence and severity of the disease (OLVERA et al., 2006b; RAPP-
GABRIELSON et al., 1997; SOLANO-AGUILAR et al., 1999). The production losses 
incurred by the disease are immense and are reflected in nursery mortality, 
decreased weight gain, and lower meat value at slaughter (OLIVEIRA and PIJOAN, 
2004). 
The pathogenic outcome of an infection depends on the immune status of an animal 
(NIELSEN and DANIELSEN, 1975). Various authors have shown that a swine herd 
may be infected simultaneously with different serovars of HPS, which may occur 
solely or in combination within a pig (RAPP-GABRIELSON and GABRIELSON, 1992; 
SMART et al., 1989). Furthermore, the prevalent serovar within a pig and 
subsequently within a herd can change over time (KIRKWOOD et al., 2001). Current 
trends recognize serovar 5 as one of the most virulent and most prevalent serovars 
in swine herds capable of eliciting sudden death and systemic infection in swine. Due 
to the considerable genotypic diversity of HPS strains (DE LEY et al., 1990; 
DEWHIRST et al., 1992; KIELSTEIN and LEIRER, 1990; RAPP-GABRIELSON et al., 
2006), vaccination strategies are not always effective. 
Alternative methods of control are essential and the prudent use of antimicrobials is 
considered to be an important component in the control of the septicemic spread of a 
HPS infection within a pig (DONE, 1999; MACINNES and DESROSIERS, 1999; 
RAPP-GABRIELSON et al., 2006). Antimicrobials have the advantage of not 
requiring specific knowledge about maternal antibody status nor of the dominant HPS 
serovar present in an infected herd (MCORIST and BOWLES, 2009). Experimental 
models of HPS infection are necessary to identify the clinical effectiveness of 
antimicrobial agents. However, the reproduction of systemic infection in pigs is 
difficult since HPS is a commensal of the upper respiratory tract of healthy pigs and 
most swine have a certain degree of protective immunity. So far HPS challenge 
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models have been restricted to using specific-pathogen-free (SPF) or caesarian-
derived-colostrum deprived (CDCD) piglets (BAK and RIISING, 2002; MACINNES, 
2003). Although clinical and pathological lesions of HPS can be successfully 
reproduced in such pigs due to their immune status, study success depends heavily 
on the use of antibiotics and gnotobiotic conditions; all entailing a very high cost 
(BLANCO et al., 2004).  
Tulathromycin, a triamilide, is an approved antimicrobial in many countries and has 
demonstrated efficacy in reducing the incidence and severity of some respiratory 
disease caused by certain pathogens in swine including HPS (HOOVER, 2009; 
NANJIANI et al., 2005). Its duration of efficacy against HPS beyond 2-3 days after 
metaphylactic treatment, however, has not been fully demonstrated. The objective of 
this study was to evaluate the efficacy of two different tulathromycin treatments in 
commercially weaned piglets challenged intratracheally with HPS serovar 5. 
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2 Literature review 
2.1 Haemophilus parasuis 
2.1.1 Etiology  
Haemophilus parasuis (HPS) is the causative agent of Glässer’s disease. This 
disease is characterized by serofibrinous to fibrinopurulent serositis and polyarthritis 
in swine (NICOLET, 1968; RAPP-GABRIELSON et al., 2006). Pneumonia, sudden 
death, high morbidity and mortality in naïve swine herds has also been reported 
(MINIATS et al., 1986). In 1910, GLÄSSER (1910) first recognized the association 
between the presence of the bacteria with the occurrence of fibrinous serositis and 
polyarthritis in swine, and isolation of this organism was done by SCHERMER and 
EHRLICH in 1922 (LITTLE, 1970). Later in 1943, HJÄRRE and WRAMBY first 
identified the bacterium under the name Haemophilus suis. The first Haemophilus 
species, however, was identified in 1892 by Richard Pfeiffer. Haemophilus suis 
requires both X (iron porphyrin), and V (nicotinamide adenine dinucleotide = NAD) 
factors for growth (NEDBALCOVA et al., 2006). The name Haemophilus parasuis 
was suggested by BIBERSTEIN AND WHITE (1969) since they could demonstrate 
that the etiological agent of Glässer’s disease only required the V growth factor 
hence the “para” before “suis”. Factor V is present in heated blood and is also 
synthesized by some bacteria e.g. Staphylococcus spp. (RAPP-GABRIELSON et al., 
2006). 
HPS, a gram-negative bacterium, belongs to the family Pasteurellacae although its 
exact position within the family has not been fully determined due to its considerable 
genotypic diversity (DE LEY et al., 1990; DEWHIRST et al., 1992; KIELSTEIN and 
LEIRER, 1990; RAPP-GABRIELSON et al., 2006). The bacterium is less than 1 µm 
in size, non-motile and capable of variable lengths and forms (NEDBALCOVA et al., 
2006; RAPP-GABRIELSON et al., 2006). Many HPS strains appear to possess a 
polysaccharide capsule but capsule expression possibly depends on the culture 
medium (MOROZUMI and NICOLET, 1986a; RAPP-GABRIELSON et al., 1992). 
Furthermore, the noncapsulated strains have specific rod-like to filamentous 
morphology in contrast to the cocobacillary form of capsulated strains (MOROZUMI 
and NICOLET, 1986b). HPS forms colonies on chocolate agar which are usually 
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round with a slight conical surface, nonhemolytic, translucent and odorless (RAPP-
GABRIELSON et al., 2006). 
Since other members of the family Pasteurellacae are nonhemolytic and either NAD 
and or V factor dependent, biochemical differentiation is necessary to identify HPS. 
HPS can be differentiated from other members of the Pasteurellacae based on its 
ability to illicit a negative urease and oxidase reaction including a positive catalase 
reaction. HPS also has the ability to ferment such sugars as glucose, galactose, 
fructose, mannose, maltose, sucrose, and reduce nitrates. In addition to these 
biochemical properties, HPS does not produce indol (KIELSTEIN et al., 2001).  
BAKOS et al. (1952) described the first HPS serovars based on observations made 
after a precipitation test to examine the existence of HPS serovars. These serovars 
were assigned the letters A through D. Thirty four years later, MOROZUMI and 
NICOLET (1986a) described an additional 7 serovars after serotyping isolates from 
Switzerland and Japan, and designated the numbers 1 through 7. KIELSTEIN et al. 
(1991) identified 6 further serovars (Jena 6- Jena 12), and later in 1992 an additional 
5 (ND1-ND5) were identified (RAPP-GABRIELSON and GABRIELSON, 1992). A 
standardized serovar classification was first defined by KIELSTEIN and RAPP-
GABRIELSON in 1992. They suggested a novel classification based on the results of 
an immunodiffusion test with heat-stable rabbit antigen. According to this now 
internationally recognized nomenclature, the previous strains 1-7 retained their 
original classification but all other strains were designated numbers until a total of 15 
serovars were established. 
In addition to these serovars, there exist numerous nontypeable isolates. After 
examining 103 HPS Danish field isolates, ANGEN et al. (2004) reported that 15 % of 
the isolates were nontypeable. OLVERA et al. (2007a) also reported similar figures 
after investigations of a Spanish farm. In Germany, the percentage of nontypeable 
isolates is approximately 26 % (KIELSTEIN and RAPP-GABRIELSON, 1992), and in 
China 12 % (CAI et al., 2005). It has been postulated that the existence of so many 
nontypeable isolates may be due to the insufficient type-specific antigen expression, 
the existence of further serovars or the highly genetic diversity within serovars 
(RAPP-GABRIELSON et al., 2006). 
The high genetic variance among HPS serovars is the focus of many epidemiological 
studies worldwide (BLACKALL et al., 1997; DE LA PUENTE REDONDO et al., 2003; 
NEDBALCOVA et al., 2006; RAPP-GABRIELSON and GABRIELSON, 1992; RUIZ et 
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al., 2001; SMART et al., 1988). Based on molecular techniques such as 
Enterobacterial Repetitive Intergenic Consensus polymerse chain reaction (ERIC-
PCR) testing, wide strain variation within serovar groups was identified (OLIVEIRA et 
al., 2003a; RAFIEE et al., 2000; RUIZ et al., 2001). A total of 12 different strains were 
detected for serovar 4 (OLIVEIRA et al., 2003b). One strain was identified for serovar 
5, 2 strains for serovars 1, 3 and 7, 3 strains for serovars 12 and 14 and 4 strains for 
serovar 2. 
2.1.2 Epidemiology 
2.1.2.1 HPS prevalence  
Since the introduction of herds with high health status, increased spread of the 
disease has been reported (DE LA FUENTE et al., 2007). RITZMANN and 
HEINRITZI (2005) noted that transport, mixing swine from different herds, 
introduction of naïve animals into infected herds, feed changes, and poor stall climate 
are supporting factors in the development of an HPS infection in a herd. Furthermore, 
because of the lower prevalence of infected animals and heterogeneity of HPS strain, 
specific-pathogen-free (SPF) and segregated-early-weaning (SEW) herds are more 
affected than commercial one-site farms (PIJOAN and OLIVEIRA, 2002). 
MACINNES et al. (2008) and MINIATS et al. (1986) performed comprehensive 
studies in Ontario and southwestern Ontario swine herds. Both studies found 
conclusive evidence of widespread HPS in swine herds. A previous study by SMART 
et al. in 1989 in Ontario SPF herds showed that more than 70 % of the herds were 
positive for HPS. After examining over 400 isolates from southeast China, LI et al. 
(2009) found a wide prevalence of HPS. HPS prevalence has even been 
documented in feral pigs. OLVERA et al. (2007b) described the presence of HPS in 
wild boars in north-eastern Spain. A prevalence of 18 % was reported in wild boars in 
Slovenia (VENGUST et al., 2006). REINER et al. (2007) determined that HPS was 
present in 58.6 % of tonsil and lung samples from wild boars in Germany. In some 
German states, this prevalence was nearly 100 % making wild boars a possible HPS 
reservoir. 
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2.1.2.2 Serovar prevalence 
In addition to HPS prevalence studies, several studies were carried out worldwide to 
determine the prevalence of the individual HPS serovars. Generally, serovars 4 and 5 
are the most prevalent serovars worldwide (ANGEN et al., 2004). In Germany, 
serovars 4 and 5 appear to occur most frequently followed by serovars 2, 1, 7, 12, 
13, and 14 (KIELSTEIN and RAPP-GABRIELSON, 1992; KIELSTEIN et al., 2001). 
After examining Danish isolates, ANGEN et al. (2004) found that serovar 5 was most 
prevalent followed by serovar 4 and serovar 13. The remaining serovars 1, 2, 3, 6, 7, 
9, 12, 14, and 15 were present in small numbers. In contrast, serovar 10 was the 
most dominant serovar reported in UK followed by serovars 4, 5 and 7 (MORRIS et 
al., 2006). In North America, TADJINE et al. (2004) determined that serovars 4, 5, 13 
and 7 were the most prevalent serotypes after examining 300 isolates. Serotyping of 
isolates from Australia, China, and Japan described similar trends (RAPP-
GABRIELSON et al., 2006).  
2.1.2.3 HPS in swine 
HPS is a swine specific pathogen and can be isolated from the nasal cavities, the 
tonsils, the trachea, and the lungs of healthy pigs (KIRKWOOD et al., 2001; MOLLER 
and KILIAN, 1990; OLIVEIRA and PIJOAN, 2004; OLVERA et al., 2006a; RAPP-
GABRIELSON et al., 2006). Some serovars can be isolated from either the 
respiratory tract or systemic sites (OLIVEIRA et al., 2003a; OLIVEIRA et al., 2003b; 
OLVERA et al., 2006a; RUIZ et al., 2001; SMART et al., 1988). Serovars 1, 2, 4, 5, 
12, 13, 14 including some nontypeable isolates are frequently isolated from systemic 
sites such as body cavities whereas serotype 3 and other nontypeable isolates are 
found more frequently in the upper respiratory tract (OLIVEIRA et al., 2003b). 
ANGEN et al. (2004) observed the higher prevalence of serovar 4 in respiratory 
cases and the presence of nontypeable isolates in systemic infection. RAPP-
GABRIELSON (1993) suggested the possibility of a subpopulation of HPS strains 
existing in the respiratory tract which cause systemic infection. 
The HPS infection is enzootic and direct animal contact is necessary for transmission 
(AMANO et al., 1996). Sows are generally viewed as the reservoir for HPS in infected 
herds (HAEDKE, 2008). Occurrence of the disease in such herds are infrequent and 
clinical signs are often less severe. The introduction of new virulent strains can occur 
in swine of all age groups and prevalent serovars can persist for up to 1 year in 
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infected herds (OLIVEIRA et al., 2003b; OLIVEIRA et al., 2004b; RAPP-
GABRIELSON et al., 2006). Despite the high heterogeneity among HPS strains, only 
2 to 3 prevalent strains are normally involved in mortality within a swine herd 
(OLIVEIRA et al., 2003b; OLIVEIRA et al., 2004b; RAFIEE and BLACKALL, 2000; 
RUIZ et al., 2001). Experimental studies demonstrated morbidity between 50-70 %, 
in some cases even 90 % was reported. Lethality was nearly 10 % (VOS, 2004; 
WIEGAND et al., 1997). 
Piglets are usually infected from their mother within a few days after birth. PIJOAN 
and OLIVEIRA (2003) were able to isolate HPS from the upper respiratory tract of 
newborn piglets as early as 5 days of age. Sows shed both pathogenic and non-
patogenic strains during suckling (NEDBALCOVA et al., 2006). Therefore 
colonization by virulent and avirulent HPS serovars in a litter can increase with 
increasing time spent with the sow (KIRKWOOD et al., 2001; OLIVEIRA and 
PIJOAN, 2004), and litters from older sows have a higher colonization level than 
younger sows (TURNI and BLACKALL, 2007). However, relatively few piglets are 
infected before weaning since HPS shedding in sows is low and the prevalence of 
HPS among piglets is relatively low (HAEDKE, 2008). 
Practical experiences show that the ability to induce HPS infections depends on the 
titer of maternal antibodies of the young pig (JAYAPPA et al, 1998). Antibodies 
associated with protective immunity against HPS appear to be serovar specific, and 
different strains of HPS offer little cross-protection to pigs infected with other strains 
(MCORIST and BOWLES, 2009; OLIVEIRA and PIJOAN, 2004). HPS maternal 
antibodies normally decrease after the fifth or sixth week of life but the immune 
competence in weaned piglets occurs much later after weaning. This explains the 
typical occurrence of the disease at the age of five-six weeks after stressful 
experiences such as weaning (OLIVEIRA and PIJOAN, 2002; SOLANO-AGUILAR et 
al., 1999). Development of the disease is triggered when a piglet becomes infected 
with HPS before weaning. An immune response occurs in the infected piglet and this 
animal becomes a subclinical carrier of HPS, assuming that sufficient protective 
colostral antibodies were consumed. However, in situations where insufficient 
colostral antibodies are consumed, then that pig may develop clinical signs of 
Glässer’s disease. Other piglets which are not infected, but are still under the 
protection of maternal antibodies up to the fifth or sixth week of life, are highly 
susceptible for infection after this period (NEDBALCOVA et al., 2006). Furthermore, if 
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piglets are mixed after weaning from different farm sources that have a different flora 
of HPS, then piglets will lack protective maternal antibody and develop symptoms of 
Glässer’s disease (MCORIST and BOWLES, 2009). 
2.1.2.4 HPS co-infections with other pathogens  
Various studies report about different co-infections between HPS and other swine 
pathogens (OLIVEIRA et al., 2001b). KIM et al. (2002) examined Korean pigs farms 
for the presence of porcine circovirus type 2 (PCV-2) and found that HPS occurred in 
32 % of the examined cases that were also positive for PCV-2. KUKUSHIN and 
BAIBIKOV (2007) found in 10 from 12 farms a coinfection with HPS, PRRSV and 
PCV-2. However, PALZER et al. (2007b) did not find a significant association 
between PCV-2 and HPS after examining collective serosal swabs from infected 
pigs. However, the same author found a significant association between PRRSV and 
HPS. TIMINA et al. (2005) detected in 55.5 % of Russian pigs suffering respiratory 
symptoms a co-infection of HPS and PCV-2. Mean nasal colonization by HPS were 
higher in pigs that were infected with Bordetella bronchiseptica prior to intranasal 
inoculation with HPS serovar 4 (BROCKMEIER, 2004). 
Some field observations suggest that HPS plays a significant role in the swine 
respiratory disease complex either as a predisposing agent or a primary agent 
(BROCKMEIER, 2004; KIELSTEIN et al., 1994; MULLER et al., 2003; SOLANO-
AGUILAR et al., 1999). Trends show that HPS isolation has increased with the 
increased prevalence of Mycoplasma pneumonia including viral respiratory agents 
such as porcine reproductive and respiratory syndrome virus (PRRSV), swine 
influenza virus, and porcine corona virus (RAPP-GABRIELSON et al., 2006). 
KOBAYSHI et al. (1996) frequently isolated HPS from the lungs of 51.2 % of piglets 
that were infected with PRRSV which displayed clinical symptoms of the disease. 
Higher clinical scores were recorded in animals that were dually infected with PRRSV 
and HPS than in a monoinfection of both pathogens (PALZER et al., 2007b). A 
significant association between the HPS and Mycoplasma hyorhinis was 
demonstrated after identification of HPS genome from collective serosal swabs 
(PALZER et al., 2006b). After PCR analysis, STRUTZBERG-MINDER et al. (2008) 
detected a significant association between the identification of HPS and Mycoplasma 
hyorhinis in animals that had a serositis. Further studies are necessary to investigate 
the mechanism responsible for such dual infections.  
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2.1.3 Experimental infection 
Several experimental infections have been developed using not only swine but also 
other species to study the virulence mechanism, pathogenesis of HPS and immune 
response towards HPS. In addition to these investigations, further experiemental 
models were tested to evaluate efficacy of antimicrobial treatments and vaccines. 
Such investigations usually require high doses of challenge inoculum to produce 
characteristic HPS lesions (MACINNES, 2003). BLANCO et al. (2004) found a 
positive relationship between the size of inocula and infection observed in sow reared 
and colostrum-deprived piglets. 
Pigs used predominantly in HPS experiments are often SPF, colostrum-deprived 
(CD), or caesarean derived-colostrum-deprived (CDCD) pigs (BLANCO et al., 2004). 
The main advantage of using such animals compared with commercial pigs is the 
lack of prior colonization by HPS and interference due to maternal antibodies (RAPP-
GABRIELSON et al., 1997; VAHLE et al., 1997). BLANCO et al. (2004) assessed 
disease development in sow reared and CD piglets after they were inoculated 
intratracheally with 106 to 109 CFU HPS serovar 5. Better disease development was 
observed in the CD pigs which developed typical symptoms and lesions of Glässer’s 
disease than the sow reared pigs. OLIVEIRA et al. (2003b) confirmed the use of 
naturally farrowed, colostrum-deprived piglets as an alternative model to study HPS 
infections. The advantage of this model is the easy availability of animals even from 
herds which are HPS positive. However, the success of this model depends heavily 
on strict hygiene regimes and the use of antibiotics. Although the survival rate of 
these pigs has reached 80 %, high prechallenge death losses still occur (OLIVEIRA 
et al., 2003b). 
Based on the current literature, intratracheal inoculation is the most frequent 
technique used in experimental studies. DE LA FUENTE et al. (2008a) challenged 
male 13-week old CD piglets with 109 CFU of HPS serovars 2, 4, and 5 to evaluate 
different vaccine formulations. Glässer’s disease was observed in pigs which did not 
receive any vaccines. In a study to assess the antimicrobial efficacy of soluble 
florfenicol, IGLESIAS et al. (2002) experimentally inoculated weaned piglets with 108 
CFU of a HPS solution. Two challenged-unmedicated animals were found dead 
shortly after infection and an overall lower weight gain was seen in the surviving 
challenged-unmedicated animals. To study the distribution and localization of PRRSV 
and HPS, SEGALES et al. (1999) infected 13 to 16-day old conventional pigs by the 
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intractracheal route with a reference strain of HPS serovar 5. Based on 
immunohistochemical and bacterial isolation results and clinical symptoms, pigs were 
infected with HPS. To investigate the protective role of maternal antibodies against 
HPS infection, SOLANO et al. (1999) infected piglets from vaccinated gilts, 
vaccinated and nonvaccinated piglets approximately 3 and 4 weeks of age with 106 
CFU of HPS serovar 5. Pigs originating from gilts which were not vaccinated 
displayed severe signs of HPS infection and macroscopic lesions of polyserositis and 
pneumonia were also observed. 
Another infection route which also reflects the natural path of infection in pigs is the 
introduction of HPS via the nasal cavities. BROCKMEIER (2004) inoculated 3 to 4 
week old piglets intranasally with 105, 106 and 107 CFU of HPS serovar 4 and 
determined that prior infection with Bordetella bronchiseptica increases nasal 
colonization by HPS. To demonstrate the relationships between bacteria and 
pathological lesions using the immunoperoxidase technique, AMANO et al. (1996) 
inoculated 7 to 13-week old SPF pigs intranasally with 106 to 1010 CFU of strains 
from serovar 1 and 5. Eleven from thirteen pigs which died between days 1 and 6 
had septicemic lesions consistent with Glässer’s disease. VAHLE et al. (1995) could 
reproduce clinical signs and lesions of polyserositis and polyarthritis after intranasal 
infection of 5 week old CDCD with 109 CFU of a virulent HPS field strain. One study 
reported inoculating 23 to 26 day old piglets with 1 x 105 CFU of HPS serovar 5 via a 
nebulizer to test the efficacy of tilmicosin (MACINNES et al., 2003). Lower mean final 
body weights, average daily weight gains and total feed intakes including higher 
clinical scores, gross lesions, culture and mortality were seen in pigs which were not 
administered tilmicosin. 
The infection of pigs via the intraperitoneal route is based on previous studies 
performed on mice and guinea pigs. SIDROV et al. (1977) found that inoculation of 
guinea pigs resulted in disease similar to Glässer’s disease. After this discovery, 
MOROZUMI et al. (1981) inoculated both mice and guinea pigs with varying doses of 
HPS serovar 5 to examine the pathogenicity. Mice which were inoculated 
intraperitoneally with 109 CFU died but those infected with 107 to 108 CFU remained 
unaffected. Guinea pigs were inoculated by nasal, intranasal, intrapulmonary, 
abdominal, intramuscular, subcutaneous, oral, and conjunctival routes with 108 to 
1010 CFU. Lesions were seen after intramuscular or intrapulmonary infection in the 
guinea pigs. Noticeable was that the infection of mice required high numbers of cell 
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to elicit disease in comparison to guinea pigs. In a similar study, RAPP-
GABRIELSON et al. (1992) inoculated guinea pigs intratracheally and 
intraperitoneally to compare the virulence of HPS serovars 1 through 7. Serovars 1 
and 5 were identified as the most pathogenic causing morbidity or death at higher 
doses. Later, BAK and RISSING (2002) infected commercial pigs of varying ages by 
the intraperitoneal route with different strains of serovar 5 using 107 and 108 CFU to 
test vaccine efficacy. Most of the control animals that were infected at 8 weeks of age 
became severely ill whereas those infected at 15, 17, 24 weeks of age developed 
varying degrees of clinical disease. FRAYSSINET et al. (2004) successfully infected 
4 to 5 week old piglets intraperitoneally with 1 x 108 CFU of HPS to test antimicrobial 
efficacy of amoxicillin via drinking water. According to OLlVEIRA and PIJOAN, (2004) 
development of clinical symptoms and lesions of disease in conventional pigs after 
intraperitoneal infection are dose-dependent. Pigs inoculated with high doses of HPS 
such as 108 to 109 CFU developed fibrinous polyserositis, arthritis, and meningitis 
whereas pigs with lower doses did not develop lesions. 
A rather seldomly used method of infection is the intramuscular route. Clinical signs 
and postmortem lesions of Glässer’s disease were seen when CDCD pigs were 
infected using this route to evaluate the duration of immunity in vaccinated pigs 
(SICK and HAYES, 2002). 
Other experimental studies focused on developing new culture media or dilution 
techniques to produce more effective inoculum for experimental infection. O’ REILLY 
and NIVEN (1986) investigated tryptone-yeast extract broth as a culture medium. 
This broth supports HPS growth and produces exponential and early stationary 
phase cultures of optimum viability. Such cultures may be suited for the preparation 
of challenge inoculum if consideration is taken by the selection of suspension fluid 
and storage conditions. MOROZUMI and HIRAMUNE (1982) successfully 
demonstrated that HPS survival in saline and phosphate-buffered-saline (PBS) is 
temperature dependent. Other culture attempts were successful if the growth medium 
contained defibrinated sheep blood, horse or bovine blood instead of the commonly 
used whole sheep blood (AMANO et al., 1994; ANGEN et al., 2007; KILIAN, 1976; 
PIJOAN et al., 1983). 
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2.1.4 Pathogenesis and virulence 
2.1.4.1 Pathogenesis  
The pathogenesis and virulence factors of HPS are not fully defined. Therefore 
factors predisposing colonization and septicemic spread need to be confirmed. 
RITZMANN and HEINRITZI (2005) reported a clear affinity of HPS to serosal 
surfaces. Replication at serosal surfaces produces typical fibrinosuppurative 
polyserositis, polyarthritis and meningitis (AMANO et al., 1994; VAHLE et al., 1995). 
After experimental infection, VAHLE et al. (1995) isolated HPS in the nasal cavities 
and trachea 12 hours after infection, in blood 36 hours later, and afterwards from 
systemic tissues up until 108 hours post infection. Later studies by 
immunohistochemistry and transmission electron microscope confirm the early 
colonization of the nasal cavity particularly the middle and caudal cavities and the 
trachea (VAHLE et al., 1997). 
Septicemic spread was observed after lesions indicative of petechiae or ecchymoses 
in the liver, kidney, meninges were detected (AMANO et al., 1994). For HPS to cause 
meningitis, the blood-brain barrier, composed of brain microvascular endothelial cells 
would have to be overcome. Studies show that HPS is able to adhere and invade 
brain microvascular endothelial cells (BOUCHET et al., 2008). Moreover, HPS 
induces apoptosis of these cells. Comparisons of the levels of adhesion and invasion 
by several HPS field strains showed that isolates of serovars 4 and 5 had a higher 
invasion capacity than isolates belonging to other serovars (VANIER et al., 2006). 
2.1.4.2 Virulence factors  
HPS serovars are known to have significant differences in their virulence (OLVERA 
et al., 2006a; RAPP-GABRIELSON et al., 2006). Furthermore, strains belonging to 
the same serovars demonstrate varying degrees of virulence (AMANO et al., 
1994;1996; NIELSEN, 1993; OLIVEIRA and PIJOAN, 2004; RAPP-GABRIELSON 
and GABRIELSON, 1992; ROSNER et al., 1991). 
Assignment of microorganism to a specific serovar group is generally viewed as an 
indicator of virulence (NEDBALCOVA et al., 2006). The virulence of certain serovars 
was demonstrated in numerous experimental challenges and epidemiological data. 
KIELSTEIN and RAPP-GABRIELSON (1992) demonstrated that among the 15 
known serovars, serovars 1, 5, 10, 12, 13, and 14 were highly virulent with the ability 
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to cause death or morbidity within four days after intraperitoneal infection in SPF 
pigs. In the same study, severe polyserositis was observed after an infection with 
serovars 2, 4, and 15 and these serovars were therefore characterized as 
intermediately virulent. Serovar 8 produced mild clinical symptoms and was classified 
as less virulent. The remaining serovars (3, 6, 7, 9 and 11) did not produce any 
clinical symptoms and were viewed as avirulent. Further studies by the same author 
support this suggested classification. Similar results were obtained after studies were 
performed in guinea pigs to examined the virulence of serovars 1 through 7 (AMANO 
et al., 1994). After examining the virulence of serotypes 1, 2, 3, and 7, ROSENDAL et 
al. (1985) identified serotypes 1 and 2 as most virulent and 7 and 3 less virulent. 
After inoculating pigs with either serovars 1 and 5, BAK and RIISING (2002) 
observed sudden death and polyserositis of varying severity. The pathogenicity of 
serovar 5 was further demonstrated in a study by TAKAHASHI et al. (2001). After 
intratracheal infections, pigs developed clinical signs of the disease and more than 
50 % of the pigs died before study termination. OLIVEIRA et al. (2004a) were able to 
induce severe clinical signs associated with HPS after infection pigs with serovar 5. 
Similar results were reported by several authors (BLANCO et al., 2004; DE LA 
FUENTE et al., 2008b; DE LA FUENTE et al., 2009a). 
 Recently, the lipooligosaccharide of HPS was shown to play a minor role in adhesion 
to new born tracheal cells (BOUCHET et al., 2009). Lipooligosaccharide is a major 
component of the outer membrane of Gram-negative bacteria and is released with 
bacterial lysis. Most biological activities of lipooligosaccharide can be attributed to 
mediators which macrophages have produced through stimulation by 
lipooligosaccharide (AMANO et al., 1997; KHAIR et al., 1996). Lipooligosaccharide is 
capable of eliciting apoptosis in endothelial and epithelial cells as well as the release 
of proinflammatory mediators and is involved in bacterial adhesion to host cells 
(SYLTE et al., 2001). AMANO et al. (1997) linked the presence of lipooligosaccharide 
in the blood of diseased pigs to endotoxin shock and disseminated intravascular 
coagulation (DIC). 
LICHTENSTEIGER and VIMR (2003) proposed neuraminidase as a possible HPS 
virulence factor. Similar to the neuraminidase from other Pasteurella spp, HPS 
neuraminidase is cell associated and it plays a possible role as nutrient supplier. 
Neuraminidase activity demonstrates the ability of a pathogen to colonize or invade 
host cells. It could be demonstrated that HPS colonies displayed greater growth after 
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in vivo passage than colonies without this enzyme when silica acid was added to the 
growth medium (LICHTENSTEIGER and VIMR, 1997).  
Another possible virulence factor is the ability to build a biofilm by some serovars. 
ZHOU et al. (2006) postulated that bacteria which are capable of producing a biofilm 
can evade the immune system of the host cell, therefore increasing the chances of 
persistent and chronic infections. In addition to evading the immune system, bacteria 
with a biofilm have a higher tolerance towards antimicrobial agents. JIN et al. (2006) 
tested the biofilm forming ability of various strains from 13 HPS serovars (with the 
exception of serovars 3 and 8) including nontypeable isolates. Only serovars 2, 9, 12, 
13 and 15 were unable to form biofilms. Also, it was shown that biofilm formation was 
retained when biofilm-forming serovars were injected into the nasal cavities of pigs. 
In contrast, this ability was lost in bacteria that colonized the lung and brain. These 
observations were later confirmed in a further study by the same author (JIN et al., 
2008). 
Some authors suggested the potential association between presence of a capsule 
and HPS virulence using experimental infections. The capsular material is thought to 
be an acidic polysaccharide although earlier studies by WILLIAMSON and 
ZAMENHOF (1964) reported a structure of repeating units of polymerized α-
galactosyl-α-N-acetylglucosaminide. MOROZUMI and NICOLET (1986a) showed the 
presence of a capsule in 12 of 32 investigated HPS strains. Generally, serovars 1, 2 
and 3 possess a capsule and serovars 4 and 5 are noncapsulated. Capsules were 
observed most often in isolates that originated from the nasal cavities. In another 
study, investigators found that noncapsulated strains were more virulent that the 
capsulated ones (KOBISCH et al., 1980). ROSNER et al. (1991) studied various HPS 
serovars and strains from different farms in Germany and found that noncapsulated 
strains and isolates of serovar 5 dominated in pigs with Glässer's disease. 
Still, other authors attribute the virulence among certain strains to the presence of 
certain outer membrane proteins (MINIATS et al., 1991a; RUIZ et al., 2001). The 
outer membrane proteins of HPS therefore may contribute to immunity and virulence. 
After sodium dodecyl sulfate polyacrimde gel eletrophorese (SDS-Page) analysis, 
results showed that strains recovered from systemic sites had more homogeneous 
outer membrane proteins than those isolated from respiratory sites (RUIZ et al., 
2001). The outer membrane proteins were identified as having two different profiles; 
biotype 1 and biotype II (MOROZUMI and NICOLET, 1986a; NICOLET et al., 1980). 
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Biotype I, with a molecular weight from 23-40 and 68 KDa, was found more often in 
the nasal cavity of healthy pigs. In contrast, biotype II which is characterized by a 
molecular weight of 37 KDa, was found in swine herds with Glässer’s disease. 
MINIATS et al. (1991a) demonstrated that pigs challenged with various strains of 
HPS survived the challenge if they were vaccinated with outer membrane proteins 
antigens prior to challenge.  
CERDA-CUELLAR and ARAGON (2008) proposed serum-resistance (normal and 
immune rabbit serum) as a possible virulent mechanism for HPS. Strains isolated 
from the nasal mucosa of healthy animals were sensitive to the bactericidal effect of 
the serum. In contrast, systemic strains were mainly resistant. 
MUNCH et al. (1992) showed that HPS was able to form fimbriae-like structures after 
in vivo passage. Bacteria fimbriae are nonflagellar proteinaceous surface 
appendages which are often necessary for adherence to host cells (BEACHEY, 
1982; STULL et al., 1984). However, the role of these structures as a virulence factor 
has yet to be clarified. 
Several molecular techniques have been employed to identify virulence-associated 
genes in bacteria. These genes are presumably active (up-regulated) in response to 
restrictive host environment. SACK and BALTES (2009) identified five potential 
virulence associated genes and the hemolysin operon (hhdBA) was found to be most 
present in investigated isolates. METCALF and MACINNES (2007) detected eight 
virulent genes of serovar 5 that were up-regulated in response to iron depletion. Iron 
is indispensable for the growth and survival of microbial pathogens in the course of 
infection. HILL et al. (2003) also conducted a search for virulence associated genes 
in strain 1185 serovar 5 HPS. Three genes appeared to be more upregulated than 
others and a total of seven gene fragments were identified.  
Based on the multitude of possible virulence factors, further studies are clearly 
necessary to confirm and detect virulence factors of HPS. 
2.1.5 Clinical signs 
HPS infection usually occurs in young pigs 4 to 6 weeks after weaning (RAPP-
GABRIELSON et al., 2006). In some swine herds, clinical signs are evident one week 
after weaning. Such early symptoms are possibly due to insufficient colostrum intake 
(OLIVEIRA and PIJOAN, 2002; ZIMMERMANN and MÜLLER, 2004). The severity of 
clinical signs depend not only on the virulence of the strain present in the herd but 
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also on the immune status and the current stage of infection (OLIVEIRA and 
PIJOAN, 2002). The incubation period is between five to seven days (BAEHLER et 
al., 1974). Incubations times of 24 hours were also reported after experimental 
infection (DE LA FUENTE et al., 2008a; DE LA FUENTE et al., 2009; NEIL et al., 
1969; OLIVEIRA et al., 2003a; VAHLE et al., 1995). In naïve herds or in swine either 
infected with highly virulent HPS strain or weakened by a preexisting disease, 
outbreaks of Glässer’s disease can occur relatively shortly after exposure to HPS 
(RAPP-GABRIELSON et al., 2006).  
Following an acute infection, clinical signs are dominated by pyrexia (41.2 °C), 
apathy, anorexia, kyphosis, pain (squealing), cyanosis, and lateral recumbency 
(RAPP-GABRIELSON et al., 2006; RITZMANN and HEINRITZI, 2005). Abortion in 
gilts and chronic lameness in boars following an acute infection have also been 
reported (RAPP-GABRIELSON et al., 2006). Sudden death is seen most often in 
young piglets after septicemia spread of the infection (HILL et al., 1996; PIJOAN and 
OLIVEIRA, 2002; RAPP-GABRIELSON et al., 2006). Auscultation of lungs frequently 
results in pleural friction rub if a pleuritis is present. Further respiratory symptoms 
often observed include coughing and dyspnoea. Palpation of the hock, the tarsal and 
carpal joints reveal increased synovial fluid (RAPP-GABRIELSON et al., 2006; 
RITZMANN and HEINRITZI, 2005). Following such changes, lameness can be 
observed to varying degrees of severity. If the meninges become infected, neurologic 
deficits such as ataxia, tremor, spasms, nystagmus, and paddling have been 
reported (KIELSTEIN, 1985). In one rare case, panniculitis of the ears, myositis and 
fascitis of the neck musculature including edema of the head region was observed in 
SPF sows (HOEFLING, 1991;1994). Chronic infection is manifested by rough hair, 
body weight loss and poor growth (RAPP-GABRIELSON et al., 2006). In endemically 
infected herds where mostly older animals are affected, clinical symptoms are less 
evident than in naïve herds and are mostly restricted to symptoms of respiratory 
distress (OLIVEIRA and PIJOAN, 2002). 
Blood examination of pigs experimentally inoculated with serovar 5 detected DIC, 
severe leucopenia, hypoglycemia, prolonged prothrombin and activated partial 
thromboplastin time, and increased fibrinogen-fibrin degradation (AMANO et al., 
1997). After inoculation of SPF pigs with HPS serovar 5, endotoxin could be detected 
in the plasma of all the inoculated pigs from 16 hours post-infection until death, and 
its concentration rose dramatically just before death of the animal. All pigs died 28 to 
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42 hours after challenge (AMANO et al., 1997). A severe leucopenia was seen 24 
hours after challenge until death. HEINRITZI (2006) noted that the blood leucocytes 
level decreases 1 to 2 days after an infection only to then dramatically rise 
afterwards. 
2.1.6 Gross and microscopic lesions  
2.1.6.1  Gross lesions 
The severity of macroscopic lesions displayed often depends on the duration of the 
infection (SCHULZ, 1991). Macroscopic lesions by an HPS infection generally 
consists of serofibrinous or fibrino-purulent exudates on the pleura, pericardium, 
peritoneum or joint surface (hock, carpal and tarsal joints) all occurring in various 
combinations. (BLANCO et al., 2004; BLANCO et al., 2008; NEDBALCOVA et al., 
2006; SOLANO-AGUILAR et al., 1999). By chronic infections, adherences in pleura, 
pericardium, and peritoneum are frequently present including hydrothorax, 
hydropericardium and hydroperitoneum (BLANCO et al., 2004). In some cases 
severe fibrino-purulent adhesions of the gastrointestinal tract with fibrin deposits on 
the surface of all abdominal organs can be observed (TURNI and BLACKALL, 2007). 
Organs generally appear hyperemic with petechiae or ecchymoses evident in the 
cardiac coronary sulcus, the liver, the kidneys, and the meninges (AMANO et al., 
1994). Following septicemic spread, enlarged lymph nodes especially the mesenteric 
and mediastinal lymph nodes can be seen (DE LA FUENTE et al., 2008a). 
Thrombosis of the lungs, lymph nodes, kidneys, liver, and brain occurs infrequently. 
Lesions mainly in the cranial lung lobes are evident following an exudative or 
bronchopurulentpneumonia after HPS infection (AMANO et al., 1997; DE LA 
FUENTE et al., 2008a). OLIVEIRA and PIJOAN (2002) reported finding antero-
ventral consolidation of the lungs with purulent exudates in the bronchi and 
bronchioli. Infrequent cases of purulent rhinitis were also reported by VAHLE et al. 
(1995). If a septicemia accompanies an HPS infection, subcutaneous and pulmonary 
edema including the occurrence of sudden death without the typical inflammatory 
lesions on the serosal surfaces may also be observed (RILEY et al., 1977). 
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2.1.6.2 Microscopic lesions 
Histological findings in serofibrinous to fibrino-purulent inflammations usually consist 
of infiltrates of fibrin, neutrophils, lymphocytes and to a lesser extent macrophages 
(NEDBALCOVA et al., 2006; VAHLE et al., 1995). Fibrinous microthrombi were 
observed in organs that had petechiae or ecchymoses and in the capillaries of the 
pulmonary alveolar walls of some pigs (AMANO et al., 1994). This author also found 
fibrinopurulent meinigitis in several pigs. A mild to moderate splenitis with neutrophils 
attached to the capsule was noted by SOLANO-AGUILAR et al. (1999) after 
intratracheal infection in pigs with serovars 4 and 5. In a similar study, spleen lesions 
were characterized by perifollicular hemorrhage, perifollicular necrosis and fibrinious 
serositis (NOGUEIRA et al., 2000). AMANO et al. (1994) observed a depletion of 
periarteriolar lymphoid tissue and follicles in the spleen with hemorrhages in the 
marginal zone of white and red pulp of some pigs infected intranasally with serovars 
1, 4 and 5. After experimental infection, fibrinous thrombi in the renal glomeruli and 
necrosis of renal tubules, with calcification and non-purulent interstitial nephritis were 
observed (DE LA FUENTE et al., 2008b; SOLANO-AGUILAR et al., 1999). The 
parenchyma of enlarged lymph nodes contains increased numbers of mononuclear 
or polymorphonuclear cell infiltrates and germinal centers are activated (NOGUEIRA 
et al., 2000; OLIVEIRA and PIJOAN, 2004). Lung lesions are characterized by 
infiltrates of neutrophils and macrophages (NEIL et al., 1969). If an exudative 
pneumonia is present, alveolar edema and edematous or serofibrinous exudates 
within the alveolar lumina and septa can also be seen. In addition, small areas of 
lung collapse as a result of bronchiolar plugging by fibrin and leucocytes can be 
found.  
2.1.7 Differential diagnosis 
Clinical signs and lesions produced by an HPS infection are often quite similar to 
symptoms produced by other viral and bacterial pathogens. Already in 1969, NEIL et 
al. (1969) discussed the similarity of the polyserositis and arthritis produced by 
Mycoplasma hyorhinis with that of HPS. Similar to Glässer’s disease, particularly 
piglets between three to ten weeks old are prone to a Mycoplasma hyorhinis infection 
(RAPP-GABRIELSON et al., 2006; RITZMANN and HEINRITZI, 2005). The 
polyarthritis caused by Mycoplasma hyosynoviae and purulent arthritis due to 
streptococcal infections or Arcanobacter pyogenes are further possible differentials. If 
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a septicemic infection is suspected, bacterial involvement by Streptococcus suis, 
Erysipelothrix rhusiopathiae, Actinobacillus suis, Salmonella cholerasuis var. 
kunzdorf and Escherichia coli need to be considered as alternative differential 
diganoses (RAPP-GABRIELSON et al., 2006). If symptoms of central nervous 
impairment are displayed, edema disease and meningitis caused by Streptococcus 
suis are possible differential diagnoses. Prominent features of edema disease are the 
subcutaneous edema of the eyelids, nose and lips; swollen joints are not typical for 
this disease (RAPP-GABRIELSON et al., 2006). Streptococcal infections are also 
characterized by swollen joints and symptoms of respiratory distress (HEINRITZI, 
2006). By respiratory symptoms or gross lesions, identification of other known viral 
and bacterial pathogens involved in the swine respiratory disease complex is 
necessary before a conclusive diagnosis can be made (RAPP-GABRIELSON et al., 
2006).  
2.2 Diagnosis 
A preliminary diagnosis of Glässer’s disease is based on the clinical signs, the 
presence of gross lesions such as polyserositis and polyarthritis, and 
histopathological investigations. A definitive diagnosis of any infection requires the 
isolation of the causal agent. In the case of HPS, isolation and identification is not 
always conclusive due to the fastidious nature of the microorganism and its 
commensal status in the upper respiratory tract of healthy pigs. 
2.2.1 Selection of animals and sampling sites 
An essential factor in the diagnosis of HPS is the use of appropriate animals and 
tissues for sampling. Successful isolation was observed when animals with clinical 
signs of HPS infection are used (OLIVEIRA, 2004). Furthermore, to optimize 
isolation, animals in the early stages of infection which have not been treated with 
antimicrobials for at least 1 week should be used (OLIVEIRA and PIJOAN, 2002). 
According to OLIVEIRA (2004), isolation from chronically affected pigs is usually 
unsuccessful. Since HPS is an epiphyte of the upper respiratory tract of healthy pigs, 
non-respiratory sites are preferred for sampling and isolation (MOLLER and KILIAN, 
1990; VAHLE et al., 1997). Ideally are sites such as the brain (meninges), the 
pericardium, the pleura, the peritoneum, and the joints (OLIVERIA; 2004). SEGALES 
et al. (1998) were able to recover HPS from the peritoneal and articular fluid. Various 
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authors were also able to isolate HPS in the pleural fluid, peritoneal fibrin and 
pericardial fluid (AMANO et al., 1997; NEIL et al., 1969; TURNI and BLACKALL, 
2007). The same authors found that the lung, the heart, the heart blood, affected 
joints and brain to be the best sites for sampling when an acute infection is present. 
However, other authors listed the isolation from blood during acute infection as 
infrequent (OLIVEIRA et al., 2003b; OLIVEIRA and PIJOAN, 2004).  
2.2.2 Sampling procedures 
Samples for HPS isolation should be collected aseptically whenever possible. 
Collection can be done using sterile swabs placed in transport systems containing 
Stuart or Amies media. The Amies system maintains viability of HPS better than 
Stuart system (DEL RIO et al., 2003). Even complete organs are suitable for 
transport. However, swabs have been successfully used for sampling diseased 
animals for diagnosis of HPS particularly by PCR (ANGEN et al., 2007). Furthermore, 
swabs allow easier handling and transportation compared with tissue samples. 
Immunohistochemical studies indicate that free HPS cells are concentrated in 
fibrinous exudates, therefore , swabs from organs with fibrinous exudates on the 
surface are preferred (SEGALES et al., 1997). Fluids from joints, peritoneum, 
pericardium, thoracic cavity are also useful and can be obtained using sterile 
syringes (OLIVEIRA, 2004). 
MOZUMI and HIRAMUNE (1982) found that HPS is temperature sensitive. The 
authors established that HPS organisms are undetectable in physiological saline at 
42 °C within 1 hour, at 37 °C within 2 hours, and at 25 °C within 8 hours. Because 
different HPS strains may be isolated from different body sites in the same pig, 
tissues samples should be submitted in separate bags. The use of formalin is not 
necessary for tissue samples (OLIVEIRA, 2004). The survival rate of HPS can be 
extended if samples are stored at 4 °C until submission to a diagnostic laboratory 
(MOROZUMI and HIRAMUNE, 1982; OLIVEIRA et al., 2004b).  
2.2.3 Bacterial isolation 
Clinical symptoms of Glässer’s disease are diverse. Therefore, bacterial isolation of 
HPS is indispensible. Since HPS is V factor dependent, NAD is supplied when the 
blood agar is heated or on NAD supplemented pleuropneumonia like organism 
(PPLO) agar. Since Staphylococcus aureus produces NAD, a nurse strain can also 
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be streaked onto a blood agar plate thus facilitating satellite growth. When a liquid 
culture is required such as for biochemical tests, HPS can be cultured in liquid 
pleuropneumonia like organism agar broth supplemented with NAD (OLVERA et al., 
2007c). HPS is a very fastidious microorganism and growth depends often not only 
on the suitable agar but also the correct atmosphere. CO2 supplemented atmosphere 
has been shown to support HPS growth (BLANCO et al., 2008; DE LA FUENTE et 
al., 2009b). Incubation time varies between 24-48 hours (SEGALES et al., 1997). 
Due to the fact that other bacteria such as Actinobacillus indolicus, Actinobacillus 
porcinius and Actinobacillus minor are also NAD dependent and are found in the 
upper respiratory tract of swine, culture in media supplemented with antibiotics such 
as lincomycin and bacitracin are sometimes necessary (PIJOAN et al., 1983). 
Nevertheless, confirmation of HPS by biochemical differentiation is necessary to 
differentiate these bacterial species. Furthermore, if samples were obtained from the 
respiratory tract, successful bacterial culture does not confirm a systemic HPS 
infection. Particularly samples from the brain (meninges), the joints, and the serosal 
membranes are suitable for bacterial culture (NEDBALCOVA et al., 2006). In addition 
to these sites, swabs from fibrinous exudates, peritoneal fluid, synovial or 
cerebrospinal fluid including samples from the liver and the spleen are also suitable 
(OLIVEIRA, 2007; RITZMANN and HEINRITZI, 2005). HPS may also be isolated 
from lungs with severe pneumonia (OLIVEIRA, 2007). MOORKAMP et al. (2008) 
proved that isolation from bronchoalveloar lavage fluid (BALF) is comparable to 
detection from lung tissue. However, PALZER et al. (2005) noted that isolation from 
BALF does not necessarily confirm a clinical infection since HPS is a commensal in 
the respiratory tract of healthy pigs. Furthermore, the same author did not find a 
significant relationship between the cultural isolation from BALF with clinical 
symptoms and gross lesions of fibrinous serositis (PALZER et al., 2006b). 
2.2.4  Molecular biological methods 
2.2.4.1 PCR 
The development of a specific PCR for HPS in 2001 was a major advance in the 
diagnosis of HPS infections particularly since HPS is such a fastidious bacterium 
(OLIVEIRA et al., 2001a). The PCR could detect a minimum of 102 bacteria and 
0.69 pg of DNA. The gene sequence for the PCR is approximately 821 base pairs 
from the 16S small subunit ribosomal RNA of HPS. The high sensitivity of this PCR 
 Literature review  22 
was demonstrated due to its detection of HPS in tissue or swab samples from 
subclinic to dead animals including pure culture (colony PCR). The PCR test could 
also detect HPS from samples of acute lesions with negative bacterial isolation 
results. It is a far more sensitive method than bacterial culturing for diagnosis of HPS 
systemic infections (OLIVEIRA et al., 2006). Most PCR positive results are obtained 
after sampling fibrinous exudates in the pleura, pericardium, peritoneum, spleen, 
liver, joints, and meninges. Results from histopathological examination show a higher 
success rate when sample material from animals in an acute infection are used 
(OLIVEIRA, 2007). However the diagnostic value of the PCR method is limited to 
sample material which does not originate from the upper respiratory tract due to the 
presence of HPS in this region in healthy pigs. Positive PCR results from the upper 
respiratory tract including the lungs are only valid if HPS was not detected prior to 
testing (OLIVEIRA, 2007). Further limitations of the PCR include a positive non-
specific reaction with Actinobacillus indolicus. This bacterium is also a commensal of 
the upper respiratory tract of pigs. Due these limitations, the PCR is suitable for 
diagnosing HPS isolates recovered from systemic tissues. 
JUNG et al. (2004) developed a nested PCR to improve the sensitivity of the 
technique. Moreover, this PCR is applicable for use by formalin-fixed, paraffin-
embedded tissues. Sensitivity was increased to 3 CFU due to the amplification of a 
313 base pair sequence. The specificity is however the same as the conventional 
PCR since the primers of the nested PCR are identical to the same gene sequence 
of Actinobacillus indolicus. 
An improved version of the original PCR by OLIVERA et al. (2001) was recently 
developed by ANGEN et al. (2007). The 16S r DNA sequence used in this PCR 
originated from the 15 known serovars of HPS. In comparison to the PCR by 
OLIVEIRA et al. (2001) which also tested positive for Actinobacillus indolicus, this 
PCR is 100 % species specific for HPS. The sensitivity of the PCR is slightly lower 
when applied on clinical samples from diseased pigs and pure HPS cultures. Also, 
the chances of false positive results of samples from systemic sites are also lower in 
the PCR test by OLIVEIRA et al. Both PCR methods demonstrated similar sensitivity 
when tested on purified DNA. Since both PCRs have similar sensitivity but differing 
specificity, their use depends on the purpose of the diagnostic (ANGEN et al., 2007). 
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2.2.4.2 In situ hybridisation 
An in situ hybridisation (ISH) for HPS was developed by JUNG and CHAE (2004). In 
situ hybridisation allows the direct association of HPS with tissues lesions similar to 
immunohistochemistry (IHC) without the problems associated with antibody 
availability. Also, this method allows the detection of HPS in formalin-fixed, paraffin-
embedded tissues (JUNG and CHAE, 2004). Since a high similarity between the 
probe used for this method and fragments in the genes of Actinobacillus indolicus, 
and Actinobacillus porcinus exists, a potential cross-reaction with these bacteria can 
occur. Further investigations are necessary to evaluate the use of in situ hybridisation 
as a routine diagnostic method. 
2.2.5  Further diagnostic methods 
2.2.5.1 Serotyping 
After bacterial culture and biochemical differentiation, HPS may be further 
characterized by serotyping. Serotyping of HPS can be performed using either 
indirect haemagglutination (IHA) or the agar gel precipitation test (AGPT) (DEL RIO 
et al., 2003a; TADJINE et al., 2004). Both techniques are based on the reaction 
between serovar-specific polyclonal antiserum and heat-stable antigens extracted 
from the bacterial cultures (OLIVEIRA, 2007). In contrast to the agar gel precipitation 
test method, the indirect haemagglutination is specific and sensitive for HPS with 
fewer cross-reactions being reported. Also a higher percentage of nontypeable 
isolates (15-40 %) was seen for agar gel precipitation test compared with the indirect 
haemagglutination test (<10 %) (OLIVEIRA and PIJOAN, 2004; TADJINE et al., 
2004). Although interpretation of agar gel precipitation test and indirect 
haemagglutination results is uncomplicated, the analysis of the results is subjective. 
Some field isolates do not produce sufficient antigen in vitro for serotyping. Moreover, 
cross-reactions between serovars are possible. Nontypeable isolates can even 
interfere with serotype assignment since they can produce cross-reactions. Also, 
nontypeable may constitute serovars for which antisera do not yet exist (OLIVEIRA, 
2007). 
An alternative method which is not only used for serotyping but also as a routine 
diagnostic method is the enzyme-linked immunoassays (ELISA). SOLANO-AGUILAR 
et al. (1999) developed a HPS ELISA using formalin-inactivated whole cells as a 
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coating antigen to study maternal antibodies and humoral response of piglets after 
vaccination. ELISA is routinely used because it is more sensitive than other assays 
and it is compatible with high volume testing. ELISA is a good method to detect 
antibodies if antigens used in the test match the serovars infecting the population 
(OLIVEIRA, 2005).  
2.2.5.2 Genotyping 
Similar to serotyping, genotyping methods are used to characterize HPS isolates. 
Genotyping is performed by sequencing either whole bacterial genomes or a single 
gene (OLVERA et al., 2007c). Currently, there exist four methods of genotyping HPS 
isolates. The first technique is the repetitive element-based-PCR pattern (rep-PCR) 
typing and consists of typing sequences which are repetitive within the HPS genome. 
Identified sequences are strain specific. The second technique is a modified version 
of the rep-PCR, enterobacterial repetitive intergenic consensus PCR (ERIC-PCR). 
These DNA sequences (ERIC elements) are distributed throughout the bacterial 
genome and are highly conserved among different bacterial species. Different strains 
have different distribution of these sequences in their genome which can be used to 
identify groups of related strains. ERIC-PCR is presently widely used to identify 
sources of strain introduction into a herd, to detect strains involved in mortality, and 
for the selection of strains to be used in autogenous vaccines (OLIVEIRA, 2007). It is 
particularly suitable for epidemiological studies since it is fast, inexpensive and 
interpretation of results is simple in comparison to other genotyping methods. 
Recently, DE LA FUENTE (2007) developed a restriction fragment length 
polymorphism (RFLP) PCR to genotype HPS strains. RFLP-PCR is based on the 
amplification of a single gene. The main advantage of this technique in comparison to 
serotyping and ERIC-PCR is that it can be used directly on clinical samples without 
the need for bacterial isolation (OLVERA et al., 2007c). A further genotyping method, 
mutlilocus sequence typing, was developed by OLVERA et al. (2006a) to overcome 
the resolution and implementation problems of the other genotyping methods. 
2.2.5.3 Immunohisotchemistry 
Immunohistochemistry (IHC) has been used to detect HPS antigen in formalin-fixed, 
paraffin embedded tissues (AMANO et al., 1994; SEGALES et al., 1997; VAHLE et 
al., 1997). Immunohistochemistry has the advantage of providing direct visual 
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demonstration of bacterical antigens in affected tissues which facilitates the 
association between the presence of antigens and histopathological changes. 
NOGUEIRA et al. (2000) found that lung and spleen showing lesions are the most 
suitable organs for detection of HPS antigen. In contrast, the same author found that 
mediastinal lymph nodes unsuitable for immunohistochemistry. 
Immunohistochemistry has not been used extensively for diagnostic purposes, since 
the availability of monoclonal antibodies to HPS is very limited and polyclonal 
antibodies have shown cross-reactivity with other bacteria such as Actinobacillus 
pleuropneumoniae (OLVERA et al., 2007c; SEGALES et al., 1997). 
2.3 Therapy 
2.3.1 Antimicrobial use in food animal production 
The use of antimicrobials is an integrate part of the food animal production system. In 
the EU, an estimated 6750 tonne of antibiotics were used for animal health purposes 
(SCHWARZ and CHASLUS-DANCLA, 2001). Tetracyclines amounted to 66 % of this 
therapeutic use while macrolides and penicillins amounted to 12 % and 9 % 
respectively. The other antimicrobial groups together comprised 12 % (BOATMAN, 
1998; SCHWARZ and CHASLUS-DANCLA, 2001). In food production, 60 % of all 
antibiotics are used mainly for swine.  
Antibiotics used in veterinary medicine are similar or structurally related to 
antibacterials used in human medicine and repeated and indiscriminate usage poses 
the risk of developing antibiotic resistance or inducing cross-resistance pertaining to 
human medicine (UNGEMACH et al., 2006). However, since antibiotics of the same 
class, such as tetracyclines, macrolides and beta-lactams have been used for 
decades in both humans and animals, resistance to these antibiotics has been 
selected for and transferred in both groups of hosts (SCHWARZ et al., 2001). Based 
on previous studies, antimicrobial use in animals and resistance resulting from such 
use generally does not account for resistance problems in human medicine 
(SCHWARZ et al., 2001). 
2.3.2 Antimicrobial treatment for HPS 
Antibiotics are used to prevent septicemic spread of the microorganism and reduce 
the severity of clinical symptoms. High doses are often need during an acute 
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outbreak of Glässer’s disease regardless of the active ingredient or method of 
administration (DESROSIERS, 1986). This is to ensure that antimicrobials actually 
penetrate into affected areas such as the joints and cerebrospinal fluids 
(NEDBALCOVA et al., 2006).  
Penicillins and tetracyclines are one of the most widely used antibiotics to combat 
HPS (SAN MILLAN et al., 2007). Cephalosporin, the combination product trimetoprim 
and sulfonamide, ampicillin, fluroquinolon, gentamycin, spectinomycin, and tiamulin 
are also effective (HEINRITZI, 2006; RAPP-GABRIELSON et al., 2006). In addition, 
in vivo experiments with tilmicosin showed good efficacy against HPS (DEROSA et 
al., 2000; MACINNES et al., 2003; PARADIS et al., 2002). Improvements in all 
clinical and growth measures were seen in challenged pigs which received tilmicosin. 
In field trials, a single intramuscular dose of ceftiofur was effective for the treatment of 
naturally occurring bacterial swine respiratory disease including HPS (MEEUWSE et 
al., 2002). Mortality rates were significantly lower and clinical cure rates higher in pigs 
that receive ceftiofur than placebo-treated pigs. FRAYSSINET et al. (2004) also 
observed significantly lower mortalities and clinical signs in pigs which receive 
amoxicillin after infection with 108 CFU of HPS. In another study, IGLESIAS et al. 
(2002) infected weaned piglets with 108 CFU of HPS to assess the efficacy of 
florfenicol against HPS. The amount and severity of clinical disease manifestations 
were lower in pigs treated with florfenicol compared to pigs from the control group. 
2.3.3 Antimicrobial susceptibility patterns for HPS 
Antibiotic use against septicemic spread of HPS can increase the potential selection 
of bacteria resistant to the antibiotic administered. In some countries, HPS is almost 
susceptible to all tested antimicrobial agents, whereas in other countries high 
resistance exists (AARESTRUP et al., 2008).  
In one German study, less than 10 % of all HPS strains were resistant towards 
tetracycline, oxytetracycline, enrofloxacine, and canamycin. 5 % of the investigated 
strains were resistance for sulfonamide (VON ALTROCK, 1998). In a Danish study, 
the susceptibility of HPS towards ampicilin, ceftiofur, ciprofloxacin, erythromycin, 
florfenicol, penicillin, spectinomycin, tetracylince, tiamulin, and tilmicosin was 
investigated. Almost all of the antimicrobial agents were sensititve for HPS with the 
exception of isolated resistance towards trimethoprim-sulfamethoxazol 
(AARESTRUP et al., 2004). DE LA FUENTE et al. (2007) tested the antimicrobial 
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susceptibility of 30 British and Spanish HPS isolates towards 19 currently available 
antimicrobial agents. British strains were mainly resistant towards ampicillin, 
gentamicin, spectinomycin, tetracycline and trimethoprim-sulfonamide. All other 
antimicrobials showed favorable susceptibility patterns. In contrast, the Spanish 
isolates were only sensitive to florfenicol. A high resistance was seen towards the 
remaining antibiotics. Correspondingly, SAN MILIAN et al. (2007) found that 14 % of 
Spanish HPS isolates were resistance towards penicillin. PEJSAK et al. (2005) tested 
40 HPS strains collected from different Polish regions to determine their antimicrobial 
sensitivity. More than 95 % of the isolates were sensitive to amoxicillin, amoxicillin 
with clavulanic acid, ampicillin, doxycycline, cefquinome, enrofloxacine, norfloxacine 
and lincosamide. Contrastingly, 85 % were moderately resistant towards penicillin, 
tetracycline, oxytetracycline, and tiamulin. Relatively high resistance patterns were 
seen towards sulfonamides and trimetoprim. In China, high levels of resistance 
amount isolates from thirteen serovars (1-5, 7-10, and 12-15) were seen for 
enrofloxacine (70.9 %) and trimetoprim-sulfamethoxazol (44.5 %). 23.6 % of the 
isolates were resistant to more than 3 antimicrobial agents (ZHOU et al., 2009). In 
contrast, Korean HPS isolates are highly resistant to tylosin, lincosamide and 
tilmicosin (KOH et al., 2006). 
2.3.4 Tulathromycin 
Tulathromycin, the active ingredient of Draxxin® Injectable Solution (Pfizer GmbH, 
Berlin), is approved in the European Union as a single dose application for the 
treatment and metaphylaxis of swine respiratory diseases (SRD) associated with 
Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma 
hyopneumoniae and HPS (EVANS, 2005). NANJIANI et al. (2005) and HOOVER 
(2009) found that tulathromycin was safe and effective in the treatment of natural 
outbreaks of SRDC. Recently, tulathromycin was demonstrated to significantly 
reduce the positive identification of HPS in BALF after a five day treatment (PALZER 
et al., 2007c). Various authors found that tulathromycin provides protection even up 
to 9 days against death and severe morbidity caused by Actinobacillus 
pleuropneumoniae in pigs (HART et al., 2006; SCHEIDT, 2007; WAAG et al., 2008). 
MCKELVIE et al. (2005) and STANFORD (2008) demonstrated the efficacy of 
tulathromycin in a swine respiratory disase challenge model using a U.K and US.A. 
Mycoplasma hypneumoniae field isolates respectively. 
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The unique structural features of this antibiotic make it the first member of a new 
macrolide class which have been termed triamilides (LETAVIC et al., 2002). 
Tulathromycin is structurally related to erythromycin which is monobasic and to 
azithromycin which is dibasic. Tulathromycin consists of a regioisomeric, equilibrated 
mixture of a 13-member ring azalide (10 %) and a 15-membered ring azalide (90 %) 
in aqueous media, both with three basic amine groups (Figure 1). The two isomers 
differ through a lactone bond formation at the C11 and C13 regions (EVANS, 2005).  
 
Figure 1: Chemical structure of tulathromycin 
The molecular formula for tulathromycin is C41H79N3O12; its molecular weight is 
806.23, and the chemical name is (2R, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)-
13-[[2,6-dideoxy-3-C-methly-3-O-methly-4-c[(propylamino)methy]-α-Lribo-
hexopyransoyl]oxy]-2-ethyl-3, 4, 10-trihydroxy-3, 5, 8, 10, 12, 14-hexamethyl-11-[[3, 
4, 6-trideoxy-3-(diamethylamino)-β-Dxylohexopyranosyl]oxy]-1-oxa-6-azacyclo- 
pentadecan-15-one (EVANS, 2005). In its raw form, tulathromycin is a white to off-
white crystalline powder that is readily soluble in water at pH 8.0. The injectable 
solution is photostable and can be stored at room temperature for 36 months.  
2.3.4.1 Pharmacokinetic properties of tulathromycin  
The efficacy of any antimicrobial is determined in part by its pharmacokinetic 
properties. In swine, tulathromycin is registered for a single intramuscular use at the 
recommended dose of 2.5 mg/kg body weight for swine of all ages. Approximately 25 
minutes after intramuscular application, the mean maximum plasma concentration in 
pigs weighing 21.0 kg and 31.3 kg was 0.616 µg//ml. One hour after administration, 
the plasma concentration was 0.58 µg/ml. Generally, lung concentrations are 24.9 to 
181 times higher than plasma concentration (EVANS, 2005). The mean 
concentration in the lung tissue is 2.840 µg/g twelve hours post injection. The 
maximum plasma concentration In the lungs one hour after application is 3470 ng/ml 
 Literature review  29 
(BENCHAOUI et al., 2004). The slow decline in lung drug concentrations is reflected 
in a lung elimination half-life of 6 days (BENCHAOUI et al., 2004; NOWAKOWSKI et 
al., 2004). The bioavailability of tulathromycin in swine is approximately 88 % 
(EVANS, 2005). Tulathromycin is metabolized slowly and the majority of drug is 
excreted unchanged in faeces and urine. The pre-slaughter withdrawal time for 
tulathromycin in swine is 33 days. 
2.3.4.2 Pharmacodynamic properties of tulathromycin 
Although most macrolides are generally considered bacteriostatic, tulathromycin 
exhibits mixed bacteriostatic and bacteriocidal activity. In comparison to other 
macrolides, tulathromycin binds to the 50S subunit of bacterial ribosomes and inhibits 
protein synthesis which leads to inhibition of cell division and cell death (EVANS, 
2005). The structure of tulathromycin is thought to render physico-chemical 
properties that enhance the displacement of magnesium ions that stabilize the 
bacterial outer lipopolysaccharide layer, thereby disrupting its structural integrity. This 
disruption facilitates all molecular forms of tulathromycin to pass through the outer 
layer and subsequently the peptidoglycan cell wall. An additional feature which 
affects intrinsic antibacterial potency relates to the observed poor affinity of 
tulathromycin for efflux pumps in bacterial membranes. With a low affinity to the efflux 
pumps, tulathromycin can accumulate in bacteria, allowing up to four times the 
normal minimum inhibitory concentration (MIC)
 
thus enhancing antibacterial efficacy 
(TRAEDER and GROTHUES, 2004). In addition to accumulating in bacteria, 
tulathromycin accumulates in blood polymorphonuclear leukocytes or neutrophils and 
alveolar macrophages and is slowly released from these cells (SIEGEL et al., 2004). 
This potential to accumulate in bacteria is the main factor inhibiting ribosomal based 
resistance as seen in other macrolides e.g. tilmicosin. Few studies exist about the 
antimicrobial resistance of relevant veterinary bacteria towards tulathromycin. 
NANJIANI et al. (2005) evaluated the susceptibility of various HPS isolates 
originating from five European countries. The average minimum inhibitory 
concentration value required of all HPS pathogens was 4 µg/ml.  
2.3.5 Prophylaxis and immunity 
Strict hygiene practices and effective management are recommended methods for a 
successful HPS prophylaxis (NEDBALCOVA et al., 2006; RITZMANN and 
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HEINRITZI, 2005). Also, other pathogens affecting the swine herd should be 
eliminated and mixing of weaned piglets of varying ages should be minimized. 
Furthermore, mixing herds from different locations should also be reduced. Any new 
introduction of pigs to a preexisting herd should be accompanied by sufficiently long 
isolation and acclimation periods to allow the development of protective immunity 
from either vaccination or natural exposure (RAPP-GABRIELSON et al., 2006). 
Since HPS is an early colonizer, practices such as segregated early weaning are 
often ineffective. Elimination of the pathogen is best achieved when coupled with 
parenteral and oral administration of high doses of antibiotics (OLIVEIRA and 
PIJOAN, 2004). However, elimination of HPS is not always suitable since the 
introduction of naïve pigs into infected herds may lead to disease with severe 
economic losses (RAPP-GABRIELSON et al., 2006). 
Several authors emphasize the importance of maternal and natural immunity for 
controlling the disease process particularly because of the septicemic nature of the 
disease (BLANCO et al., 2008; NIELSEN and DANIELSEN, 1975). Recently, the use 
of controlled exposure of young pigs to low doses of live virulent HPS strains was 
assessed as an alternative method to control nursery losses due to HPS (OLIVEIRA 
et al., 2001b; OLIVEIRA et al., 2004b). This method is based on the hypothesis that 
early colonization of piglets with the prevalent HPS strain in the presence of maternal 
immunity reduces the risk of systemic infection after weaning. Exposed pigs showed 
a reduction in mortality but this method is not suitable for sow herds currently infected 
with active PRRSV (OLIVEIRA et al., 2001b; OLIVEIRA et al., 2004a). 
Outbreaks of Glässer’s disease can be controlled by means of commercial vaccine 
(BAK and RIISING, 2002; SOLANO-AGUILAR et al., 1999) or autogenous bacterins 
(KIRKWOOD et al., 2001; SMART et al., 1993). They are either chemically 
inactivated or attenuated vaccines with either serotypes 4 or 5, a strain possessing a 
“key outer membrane protein”, or they are of unstated composition (MACINNES and 
DESROSIERS, 1999; MARTIN DE LA FUENTE et al., 2009). In Germany, the 
current HPS vaccines consists of an inactivated serovar 5 formulation for 5 week old 
piglets and a combination vaccine containing inactivated HPS serovars 4, 5, and 
Mycoplasma hyopneumoniae for pigs 1 week or older (HEINRITZI, 2006). According 
to the manufacturers, gilts should be vaccinated in two week intervals before 
introduction into the herd and similarly, sows six to eight weeks and two to three 
weeks ante partum. Piglets can be vaccinated twice either in the first or fifth week of 
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life with a two week interval. Simultaneous vaccination of sows and their piglets is not 
recommended (OLIVEIRA, 2005). 
Timing of vaccination is very important, and the most effective time to vaccinate 
depends on the occurrence of clinical signs in the herd, management, and the 
presence of protective maternal antibodies (OLIVEIRA and PIJOAN, 2002; 
RITZMANN and HEINRITZI, 2005). If problems are experienced after weaning, 
vaccination of sows is recommended to boost maternal immunity. But if pigs show 
clinical signs of disease at a later time during the growing-finishing phase, 
vaccination of the piglet is more suitable (OLIVEIRA, 2005). 
Both types of vaccines usually protect against challenge with a homologous serovar 
(HOFFMANN and BILKEI, 2002; MCORIST and BOWLES, 2009; MINIATS et al., 
1991b; PALZER et al., 2007a; SMART and MINIATS, 1989). But variable results 
have been reported concerning the lack of cross-protection between different strains 
and serovars of HPS (BAK and RIISING, 2002; RAPP-GABRIELSON et al., 1997). 
Most farms have a stable flora of endemic HPS among their pigs, but this flora 
usually varies from farm to farm in its range of specific strains of HPS due to the 
heterogeneity of strains (BLACKALL et al., 1996; KIELSTEIN and RAPP-
GABRIELSON, 1992; OLIVEIRA et al., 2003b). Therefore, as swine farm systems 
enlarge, the possibility of a single strain commercial or autogenous bacterins 
covering all strains of etiological significance on such a farm becomes more difficult 
(NEDBALCOVA et al., 2006; OLIVEIRA and PIJOAN, 2004). Thus, control of the 
disease should not be limited to vaccine programs but also changes in management 
and hygiene practices at all stages of swine production. 
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3 Material and Methods 
3.1 Study aim 
The aim of this study was to assess the metaphylactic efficacy of tulathromycin 
(Draxxin®, Pfizer, GmbH, Berlin) administered seven and four days before 
experimental infection in weaned piglets that were subsequently challenged 
intratracheally with HPS. 
3.2 Study animals 
Thirty-six castrated-male-crossbred piglets (Landrace x Large White x Pietrain), three 
weeks of age, were obtained from a commercial farrowing farm in Lower Austria. 
Piglets were randomly selected from a total 18 litters. The sow herd had no previous 
history of porcine reproductive and respiratory syndrome virus (PRRSV) or HPS. 
Serum samples of 18 sow were taken from the 18 litters from which the study 
animals originated and samples were submitted to Clinic for Swine Department for 
Farm Animals and Veterinary Public Health, Veterinary University Vienna, Austria) for 
testing by HPS ELISA (INGEZIMA® Haemophilus 11.HPS.K 1, Ingenasa, Madrid, 
Spain). This was done to facilitate the selection of serologically negative piglets for 
the study. As part of the routine piglet processing after birth, piglets were ear tagged, 
the canine teeth were shortened and an iron supplement was administered. In 
addition, piglets received Cobactan® 2.5 % (Intervet, Unterschleissheim Germany) for 
three days, and they were vaccinated against Mycoplasama hyopneumoniae 
(Hyoresp®, Merial, Paris, France) and PCV2 (Porcillis® PCV, Intervet, Boxmeer, The 
Netherlands) in their 1st and 3rd week and 2nd week of life respectively. 
The piglets were transported from the farm to the study facility directly after weaning. 
Upon arrival, the piglets were unloaded into the main room of the facility (R2, Figure 
3). Piglets were housed in their respective rooms after assignment to their treatment 
groups and allowed a 17 day acclimatization period before the first antibiotic 
treatment (Figure 2). A nursery diet (Garant, Poechlarn, Austria) was fed ad libitum in 
addition to water throughout the entire study. 
Animal care and euthanasia during this study were approved and conducted in 
accordance to the current Animal Experiments Act and in accordance with the Good 
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Scientific Praxis guidelines of the Ethics Commimission of the Veterinary University 
Vienna, Austria. This study is registered by the Austrian Federal Ministry for Science 
and Research, Department for Genetics and Animal Experiments/Testing under the 
file number GZ 68.205/0030-II/10b/2009. 
3.3 Study design 
The study was designed to evaluate the efficacy of tulathromycin by treating weaned 
piglets according to two different treatment protocols. Piglets received either a 
tulathromycin treatment seven or four days before an infection with a virulent HPS 
serovar. The study was conducted on approximately 32 consecutive days from the 
beginning of July to mid August (Figure 2). 
 
Figure 2: Experimental timeline of the study indicating arrival, treatment, challenge and 
necropsy  
Animals arrived at the Biosafety Level 3 Facility, Clinic for Swine, Veterinary 
University Vienna Austria 17 days prior to the challenge day (Day -17), and all 
animals were immediately weighed with an electronic scale that was accurate to 0.01 
kg (PS 60 SST, Bosche, Damme). The weights of each animal were recorded in an 
Excel sheet in descending order starting with the heaviest weight (Microsoft Excel; 
Microsoft Corporation). Based on this information, piglets were assigned to four 
different treatment groups (Table 1) so that a uniform weight was represented in 
each group: control (Group 1), nontreated-challenged (Group 2), tulathromycin 4 day 
pretreated-challenged (Group 3) and tulathromycin 7 day pretreated-challenged 
(Group 4). Four unique sets of ear tags with different numbers and colors were 
allocated to the four different treatment groups and the piglets were ear tagged 
accordingly.  
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Table 1: Treatment groups in the study assessing the efficacy of tulathromycin against HPS 
Group No. of pigs Treatment administered 
Challenge 
(Day 0) 
1 Control 9 none Phosphate-buffered 
saline (PBS) 
2 Nontreated-challenged 9 none 5 x 108 CFU HPS 
3 Tulathromycin 4 day pretreated-challenged 9 
2.5 mg/kg BW tulathromycin 4 
days prior to challenge 5 x 10
8
 CFU HPS 
4 Tulathromycin 7 day pretreated-challenged 9 
2.5 mg/kg BW tulathromycin 7 
days prior to challenge 5 x 10
8
 CFU HPS 
Pigs from Groups 4 and 3 received an intramuscular injection with tulathromycin on 
Days -7 and -4 respectively. On the challenge day, Day 0, pigs from Groups 2 
through 4 were inoculated with HPS serovar 5. To maintain blinding, personnel who 
administered treatments and gave the challenge dose were not involved with animal 
removals, recording clinical observations, or pathological assessments. Pigs from the 
control Group 1 received a phosphate buffered solution (PBS) instead. Clinical 
examination of all pigs occurred once daily on Days -17, -7, -4, -1 and every day after 
challenge until the termination of the study (Days 14 and 15). All animals were 
weighed on Days -17, 0 at the end of the study (Days 14 and 15) or at removal. 
Serum samples were collected from all animals on Days -17, -7,-1, 1, 3, 5, 7, 8, 9, 
11, 14, 15 and at removal for testing blood work and by APP ELISA. 
Animals that survived to study termination (Days 14 and 15) or were euthanized due 
to humane reasons were subjected to a necropsy. In addition to gross pathology, and 
microbiological confirmation by culture of all serosal surfaces, histopathological 
examinations of selected organs and tissues were also performed. Furthermore, 
serosal swabs, joint capsule, synovial and cerebrospinal fluid were investigated by 
PCR. 
3.3.1 Housing 
The study was conducted in the Biosafety Level 3 Facility (Figure 3) of the Veterinary 
University Vienna Austria, Clinic for Swine. The facility was divided into two main 
rooms which were completely separated from each other through a 2 m2 aisle. Each 
main room was further subdivided into two main pen areas used for animal housing. 
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Pens were completely separated from each other by a standard concrete wall. An 
area designated for necropsy examination was located outside the pen areas. 
For simplification purposes, the main room to the left of the aisle entrance was 
designated Room 1 (R1) and Room 2 (R2) was the room directly opposite R1. Pens 
in R1 were approximately 20 m2 and 15 m2 in size. The layout of the second main 
room (R2) was identical to the first main room. Each pen had a solid concrete floor, 
two nipple waterers and two feeding troughs. Also, each pen had its own 
slurry/manure pit, located directly under the pens, which was automatically emptied 
on a regular basis after undergoing a thermal and biological disinfection. A constant 
temperature range from 23-28 °C was maintained in both main rooms and pens.  
In this experiment, one of the pens in R1 was used to house pigs from Group 1. The 
remaining three Groups (2, 3 and 4) were housed in the R2 whereby Group 3 was 
housed in the larger pen and Group 4 in the smaller pen. Five pigs from Group 2 
were housed together with Group 3 and four were placed in the smaller pen with 
Group 4. 
 
Figure 3: Schematic diagram of the housing facility (Biosafety Level 3) for the pigs during the 
challenge 
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3.3.2 Biosecurity 
Strict delivery protocols were in place when the animals arrived and the truck driver 
did not enter the facility or assist in offloading the animals into the facility. Personnel 
entering both of main rooms, pens and material chambers had to go through a 
double-door zone with sealed door penetrations. Also, all persons were required to 
shower and change clothes before and after animal contact.  
Adjacent to each main room was a separate chamber for feed and material delivery. 
All material used during the study such as clothing, boots, syringes, and feed were 
brought into the rooms via this chamber. Care was taken to ensure that all materials 
met strict hygienic conditions. Materials were stored in a storage room (Figure 3) that 
was only accessible by personnel who were involved with the study and who did not 
have any animal contact prior to entering this room. Each main room had its own 
designated material and feed in order to prevent cross-contamination. 
Both main rooms and pens were mechanically ventilated with air flowing in and out of 
the facility after passing through high efficiency particulate air filters (HEPA). 
Ventilation systems for both main rooms and pens were operated and managed 
independently of each other. Water for the facility came from the local municipal 
water supply. The water supply for each main room and pen were sourced from 
separate pipe systems to ensure that no cross-contamination occurred. Waste water 
and slurry/manure pit sewage from each main room and pen was handled separately 
from each other. 
3.3.3 Administration of tulathromycin 
Piglets from Groups 3 and 4 received the label dosage of 2.5 mg/ kg BW 
tulathromycin on Days -4 and -7 respectively. Animals were manually restrained and 
administered the tulathromycin as a single intramuscular injection in the neck. The 
injection was performed using a sterile 21-gauge needle (Braun, Melsungen) and a 
sterile disposable 2 ml syringe (Heiland, Gallin). 
3.3.4 Preparation of challenge inoculum 
The challenge strain used in this study was a HPS serovar 5 isolate. Preparation and 
antimicrobial sensitivity testing of the challenge strain was done by the Institute for 
Bacteriology, Mycology and Hygiene, Veterinary University Vienna, Austria. The 
strain was streaked onto a chocolate agar that consisted of 10 % sheep blood agar 
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(Fiebrig Animalblood Products, Taunus) supplemented with 0.008 % nicotinamide 
adenine dinucleotide (NADH) (Sigma-Aldrich). The agar plate was incubated for 3 to 
4 days at 37 °C in an atmosphere of 7 % carbon dioxide. Colonies were harvested in 
phosphate-buffered saline (PBS) and aliquots from this medium were frozen at 
-80 °C in sterile 2 ml tubes (Eppendorf, Hamburg). The amount of CFUs in one 
aliquote was determined using serial dilution and plating. One day prior to challenge, 
Day -1, one aliquot was selected, thawed at 37 °C and the suspension was adjusted 
until the colony count was approximately 1x 108 CFU per ml. On the challenge day, a 
suspension of 5 ml (5x 108 CFU) was filled in sterile 20 ml syringes (Heiland, Gallin) 
for intratracheal inoculation. 
3.3.5 Administration of inoculum 
On Day 0,5 ml of the HPS serovar 5 was administered intratracheally to all pigs from 
treatment Groups 2 through 4. Pigs from treatment Group 1 received 5 ml PBS 
instead. To eliminate bias, personnel who administered the challenged dose were not 
involved in recording clinical observations. Prior to inoculation, the animals were 
sedated using a combination of 1.2 mg/kg BW azaperon (Stresnil®, Janssen GmbH, 
Neuss Germany) and 10 mg/kg BW ketamin (Narketan 10 %®, Vétoquinol Paris 
France). Animals were manually restrained and administered the solution 
intramuscular in the neck with a sterile 25-gauge needle (BD Microlance® 3, New 
Jersey; USA). After the animals lost consciousness, they were positioned in sternal-
abdominal recumbency and the upper jaw was fixed with a sterile gauze. A sterile 
laryngoscope (Heine Optotechnik, Herrsching) was inserted into the mouth, the 
larynx exposed and the epiglottis lid was fixed with the end of the laryngoscope. An 
open end suction catheter (Medinorm, Speisen-Elversberg ) was inserted between 
the vocal cords and into the trachea for a distance of 9 cm. The 5 ml inoculum was 
applied directly through the catheter and 10 ml of air was applied afterwards to 
ensure complete emptying of the catheter tube. After application, the tube and 
laryngoscope were quickly removed. The animals were placed in an area designated 
as the infirmary until they regained consciousness. An assisting veterinarian attended 
to the animals until they regained consciousness. Once the animals fully regained 
consciousness as determined by the assisting veterinarian, they were promptly 
returned to their pens.  
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3.3.6 Euthansia 
Animals were euthanized in order to facilitate necropsy and histopathological 
examinations. Euthanasia was performed on Days 14 and 15 or when the animals 
were removed due to humane reasons. Animals were sedated using a combination 
of 2 mg/kg BW azaperon (Stresnil®, Janssen GmbH, Neuss) and 15-30 mg kg BW 
ketamin (Narketan 10 %®, Vétoquinol Paris France). Pigs were manually restrained in 
dorsal recumbency and the solution was administered intramuscularly in the neck 
with a 25-gauge sterile needle. Afterwards, animals were euthanised with T61® 
(20 mg/kg BW embutramid, 5000 mg/kg BW mebenzoniumjodid, 500 mg/kg BW 
tetracainhydrochlorid) (Intervet, Boxmeer, The Netherlands) via intracardiac injection. 
All animals were weighed following euthanasia.  
3.4 Clinical examinations 
After challenge, pigs were clinically examined at least once daily until study 
termination. Prior to challenge, pigs were clinically examined upon arrival (Day -17), 
at each tulathromycin administration (Days -7 and -4) and on Day -1. 16 parameters 
(Table 1) were selected for clinical examination such as body condition, hair coat, 
behavior and gait. Parameters were evaluated and assigned a qualitative score with 
a numeric grading scale from 0 through 3. Pigs displaying no clinical symptoms 
received a score of 0. Rectal body temperatures (Vet-Life, Microlife Ag, Switzerland), 
changes in the joint fluid of the tarsal and carpal joints, conjunctiva, and sclera of all 
pigs were measured once daily on Days -17, -7, -4, -1 and every second day 
thereafter up to Day 11. On Days 12 and 13, the following parameters were not 
assessed: rectal temperature, sclera, conjunctiva, carpal and tarsal joints. A score of 
2 was assigned by the parameter CNS (central nervous system) when signs such as 
head tilt, opisthotonus, ataxia, lying on side or paddling were displayed. Also, the 
parameters backline, abdomen, coughing and teeth grinding received a double score 
if clinical signs were not normal. If a joint or limb area was completely swollen during 
palpation to assess joint fluid in both the tarsal and carpal joint, a score of 3 was 
assigned for that tarsal or carpal joint. A total score for clinical signs was calculated 
each day for each pig based on the sum of the scores for all 16 parameters. Animals 
with a clinical score < 4 were classified as clinically healthy, pigs with a score of 4-5 
were mildly ill, 5-6 were moderately ill and a score above 6 indicates severe illness. 
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For humane reasons, pigs were euthanized if they exhibited severe central 
impairment (lying on the side, paddling), immobility or if they were found moribund.  
Table 2: Scoring system for clinical signs of pigs challenge or not challenged intratracheally 
with HPS  
Score 
Parameter 
0 1 2 3 
Body condition very good good moderate cachectic 
Snout color pink pallor hyperaemia cyanosis 
Gait moves freely slight reluctance to 
move or rise 
difficulty in rising or 
moving, ataxie 
recumbent, unable 
to rise 
Dyspnoea absent slight dyspnea moderate dyspnoe 
labored abdominal 
breathing, open 
mouth breathing 
Tarsal joint 
filling no swelling slight swelling moderate swelling severe swelling 
Carpal joint 
filling no swelling slight swelling moderate swelling severe swelling 
Conjunctiva 
appearance pink slight hypermia moderate hypermia severe hypermia 
Behaviour attentive depression, apathy stupor coma, moribund 
Sclera 
apperance 
white, scleral 
capillaries fine 
scleral capillaries 
blurry 
scleral capillaries 
excessively filled  
Hair coat short, smooth, 
shinny rough long   
Backline straight  kypohotic  
Abdominal 
appearance flat  swollen  
Lameness absent  present  
Coughing absent  present  
Pain (teeth 
grinding) absent  present  
CNS sypmtoms absent  present 
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3.5 Necropsy 
Pigs euthanized for humane reasons prior to Days 14 and 15 and all remaining pigs 
that were euthanized at study termination (Days 14 and 15) were subjected to a 
routine necropsy examination. Particular attention was made to the pleural, 
pericardial, and peritoneal cavities and surfaces, the basal meninges, the lungs, and 
the carpal and tarsal joints when examining each pig. To eliminate bias, the 
pathologist performing the necropsies was blinded to the treatment groups.  
When an inflammation in any one of the body cavities (pleuritis, pericarditis, 
peritonitis) and its serosal membrane was observed, the presence and of lesions 
were recorded (Table 3). A qualitative score ranging from 0 to 3 was assigned for the 
presence and the extension of each individual inflammation and a total score from 
these two parameters was calculated to assign a single score for each of the three 
inflammations in each pig. A total inflammation score for each pig was summarized 
from the final score of each of the three inflammations. Animals with a total 
inflammation score of 0 had no inflammations. Pigs with scores of 1or 2 had a mild 
inflammation, 3 and 4 (moderate inflammation) and 5, 6 (severe inflammation). 
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Table 3: Assessment table for inflammation of the pleural, pericardial and peritoneal cavities 
Parameter Pleuritis Pericarditis Peritonitis 
Presence of inflammation  
0= none    
1= fibrin strands    
3= severe adhesion, 
inseparable    
Extension of inflammation  
0= 0%    
1= <30%    
2= >30%    
3= diffuse    
Total score    
Assessment of the lung was done according to a modified method as stated in 
CHRISTENSEN et al. (1999) (Table 4). To assign a lung score, the proportion of the 
area of consolidated lung tissue each of the seven lung lobes was assessed and 
recorded in percent. For each lung lobe, this percent of affected lung tissue was 
multiplied by the estimated lung capacity of that lobe (10 % each for right and left 
cranial, right and left middle and accessory lobes; 25 % each for the right and left 
caudal lobes) and the results for the seven lobes were added to obtain the total 
percent of lung affected. Each of the seven lung lobes were inspected visually and 
palpated to determine the amount of consolidation or other lesions in each of the 
lobes including the appearance of each lobe (Table 4).  
The remaining organs and the brain were assessed and assigned a qualitative score 
of either 0 (unchanged) or 1 (changed). A score of 0 was assigned if the brain was 
homogenous light pink with the surface of the gyri clearly defined and not shrunken 
or edematous. If a score of 1 was assigned, a detail description of the alteration was 
made. 
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Table 4: Lung lesion score sheet for necropsy examination  
Parameter 
Left 
cranial 
(10% of 
total 
lung) 
Left 
middle 
(10% of 
total 
lung) 
Left 
caudal 
(25% of 
total 
lung) 
Accessory 
(10% of 
total lung) 
Right 
cranial 
(10% of 
total 
lung) 
Right 
middle 
(10% of 
total 
lung) 
Right 
caudal 
(25% of 
total 
lung) 
% affected        
Consistency 
 
0= soft elastic        
1= firm    
    
Appearance 
  
0= homogenous pink    
    
1= dark red, mottled 
parenchyma    
    
3.6 Sample collection and Diagnostic 
3.6.1 Blood sampling 
Blood samples were collected from all animals on Days -17, -7 and -1 through 15 in 
regular two day intervals. Samples were also taken before an animal was euthanized 
if this occurred on a day when blood was not collected. Animals were manually 
restrained in dorsal recumbency and blood was obtained by puncturing the right 
jugular vein using either a sterile 18- or 19-gauge needle (Sterican®, Braun, 
Melsingen) depending on the animal’s weight. Blood was collected in 7.5 and 10 ml 
serum vials (Primavette® V Serum, Kabe Labortechnik, Sarstedt). Blood samples 
were centrifuged at 3000g for 10 minutes at 20 °C. Afterwards, the sera were 
collected in sterile 2.0 ml safe-lock tubes (Eppendorf, Hamburg) and stored 
at - 20 °C. Samples were submitted to the Central Diagnostic Unit of the Veterinary 
University Vienna Austria for blood work. In addition, blood samples were analysed 
for the presence of Actinobacillus pleuropneumoniae by the Institute for Bacteriology, 
Mycology and Hygiene, Veterinary University Vienna Austria. 
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3.6.2 Synovial and cerebrospinal fluid collection 
Following euthanasia, synovial and cerebralspinal fluid were obtained from all 
animals for identification of HPS by PCR. Joint fluid was collected from both tarsal 
joints and any other swollen joints. Prior to punctuation, designated areas were 
shaved, washed with antiseptic soap (Jodosept®, Vetoquinol, Paris France) and 
disinfected with 70 % alcohol. The joint was punctured with a sterile 19-gauge needle 
and the joint fluid was collected in a sterile 2 ml syringe. Cerebrospinal fluid was 
obtained either from the occipital or lumbosacral region using a sterile 14-gauge 
needle (Bovivet®, Kruuse, Langeskov Denmark) attached to a sterile 2 ml syringe.  
The appearance of the synovia and the cerebrospinal fluid from each pig were 
evaluated and assigned a qualitative score from 0 to 4 depending on the severity of 
changes observed whereby 0 represents a physiological clear synovial or 
cerebrospinal fluid; 1 = clear, light yellow; 2 = cloudy, light yellow; 3 = cloudy, amber 
4 =cloudy, flocculent, light yellow or amber (Table 5). After assessment, the synovial 
or the cerebrospinal fluid were pipetted in sterile safe-lock tubes and stored at -80 °C 
before being submitted to the Institute for Bacteriology, Mycology and Hygiene, 
Veterinary University Vienna Austria for PCR diagnostic. 
Table 5: Scoring system for the assessment of the synovial and cerebrospinal fluid 
Score 
0 = normal 
1 = clear, light yellow 
2 = cloudy, light yellow 
3 = cloudy, amber 
4 = cloudy,flocculent, light yellow or amber 
3.6.3 Collection and processing of serosal swabs 
All the serosal surfaces of each pig with the exception of the joints were swabbed 
directly after the animal was opened for necropsy. Cotton swabs (Heinz Herenz, 
Hamburg) were used to take collective samples from the peritoneum, pleura, 
pericardium, and the meninges whereby the meninges were sampled with two 
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separate swabs. Following collection, swabs were stored at -80 °C before being 
submitted to the Institute for Bacteriology, Mycology and Hygiene, Veterinary 
University, Vienna Austria for testing of HPS by PCR. Samples were also tested by 
PCR for the presence of Mycoplasma hyorhinis. 
3.6.4 Bacteriological culture  
For bacterial isolation, sterile cotton swabs in Aimes transport medium without 
charcoal (Medi Swab®, Heinz Herenz, Hamburg) were used to take samples from 4 
sites for bacterial culture. Swabs were taken aseptically from the peritoneum, pleura, 
pleural cavity and pericardium directly after the pig was opened for necropsy. 
Samples were submitted to the Institute for Bacteriology, Mycology and Hygiene, 
Veterinary University Vienna Austria and streaked within 30 minutes of collection 
onto the same chocolate agar used for preparing the challenge inoculum. The 
cultures were incubated at 37 °C for 2-3 days in an atmosphere containing 7 % 
carbon dioxide. Colonies from this agar plate were selected with a sterile loop and 
inoculated onto a second agar plate, identical to the first culture, to facilitate 
maximum growth of HPS colonies. This subculture was incubated for another 3-
4 days and the presence and appearances of HPS colonies were assessed. A 
sample was positive when at least one typical HPS colony was observed. 
3.6.5 Histopathological examination 
Postmortem samples of the lung, heart, liver, kidney, spleen, duodenum, colon, 
inguinal lymph node, left tarsal joint capsule and brain were collected in 7 % formalin. 
These samples were submitted to the Institute for Pathology and Forensic Veterinary 
Medicine, Veterinary University Vienna, Austria for histopathological examination. 
Samples were fixed in formalin for 24 hours before being placed in commercial 
embedding cassettes and then processed for an additional 24 hours in the Tissue-
Tek VIP® machine (Sakura Finetek, Netherlands). The samples were subsequently 
embedded in paraffin wax (Tissue-Tek TEC®, Sakura Finetek, Netherlands). Paraffin 
blocks were sectioned at 1-2 µm and stained with haematoxlylin and eosin (HE). 
Evaluation of these slides was performed under a light microscope by a pathologist 
blinded to the treatment group. A qualitative score was assigned for the outcomes 
from the examination. If an inflammation was not present, a score of 0 was assigned. 
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Scores ranged from 1 to 3 depending on the severity of lesions with 1 (mild), 2 
(moderate) and 3 (severe). 
3.6.6 Polymerase chain reaction (PCR) analysis for HPS 
Samples (joint capsule, joint and cerebrospinal fluid, sera and serosal swabs) for 
PCR diagnostic were submitted to the Institute for Bacteriology, Mycology and 
Hygiene, Vetmeduni Vienna Austria. DNA was extracted from the samples using the 
GenElute® Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich) according to the 
manufacture’s user guide. Approximately 250 µl undiluted DNA was obtained after 
extraction and 5 µl of DNA was used for the PCR analysis. Reagents for the PCR 
were obtained from the RedTaq® ReadyMix PCR Reaction Mix with MgCl2 (Sigma-
Aldrich Biotechnology). Identification of HPS was done according to the PCR method 
described by ANGEN et al. (2007) and primers for the PCR were those mentioned by 
Angen et al. The reaction was run on a Eppendorf Matercycler Personal® (Eppendorf, 
Hamburg) machine with the following steps: 1 cycle at 94 °C for 3 minutes, 35 cycles 
of denaturation at 94 °C for 1minute, annealing at 56 °C for 45 seconds, and 
extension at 72 °C for 1 minute. The PCR product was separated on a 1.5 % agarose 
gel (Roti®garose, Carl Roth Co KG, Karlsruhe). Following this step, the PCR product 
was visualized using ethidium bromide and UV fluorescence. Results from the PCR 
test were assigned a qualitative score whereby a positive sample was assigned the 
score 1 and a negative sample a score of 0. 
3.7 Statistics 
The statistical analysis was performed using the statistic program SPSS 17.0 for 
Windows XP. Descriptive statistics were done using either the SPSS 17.0 or 
Microsoft Office Excel 2007. An analysis of the significance was done by comparing 
Groups 1 and 2, Group 2 with 3 and 4, and finally Group 3 with Group 4. The 1 % 
level of significance using the Bonferroni correlation to eliminate error was used to 
assess statistical differences for all tests with the exception of the following 
parameters: association of detection frequencies of HPS and the results from the 
clinical examinations, gross and histopathological lesions. A 5 % level of significance 
was used for these parameters instead. With the exception of mortalitiy rates, all 
group comparisons were analyzed using the Mann-Whitney U test. The Kaplan-Meier 
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test was used to calculate overall mortalities between the individual groups. The 
comparison of the HPS detection methods was performed using a Kappa test. 
Each animal was considered a statistical unit. Animal days were calculated for each 
pig and consisted of the number of days each pig contributed to the study (from 
Day  -17 to euthanasia). Average daily weight gain was defined as body weight gain 
(from Day -17 to Day 0 and Day 0 to Days 14/15) divided by animal-days. To analyze 
clinical scores, a total clinical score was created that consisted of the sum of each 
individual clinical score for each pig. The median was then calculated from this score 
to create a group score for the individual clinical symptom. Similarly, the average was 
determined for rectal temperatures and calculated for each study group.  
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4 Results 
4.1 Screening, animal numbers and data collection 
Screening for HPS antibodies was performed by HPS ELISA using serum from 18 
sows to facilitate the selection of piglets without HPS antibodies. According to the 
manufacture, a ratio value > 0.9 is positive, 0.6-0.9 suspect and <0.6 negative. 
Sixteen samples were negative (0.27 ± 0.10) and 2 samples were suspect (0.73; 
0.66) after serological analysis. Thus piglets from sixteen litters were used for the 
study. To rule out possible  concurrent infection, collective serosal swabs were 
obtained from these piglets during the study and tested for Mycoplasma hyorhinis by 
PCR. All swab samples were negative for Mycoplasma hyorhinis. Furthermore, 
serums from these 36 piglets were also negative for Actinobacillus 
pleuropneumoniae after ELISA testing. To ensure that the HPS strain used in this 
study was sensitive for tulathromycin, an antimicrobial susceptibility test was 
performed. Test results showed that HPS was susceptible to tulathromycin and the 
minimum inhibitory concentration value (MIC) was 0.5 mg/l. 
Tissue samples collected from all 36 animals after necropsy were histologically 
evaluated either at removal (death or euthanasia) or at study termination. The lungs 
of 1 pig from Groups 2, 3 and 2 pigs from Group 4 were not examined during 
necropsy. Data from these animals were excluded from all analysis. A total of 36 
swabs from the serosal surfaces were submitted for bacterial culture and HPS PCR. 
Brain swabs from all 36 pigs were also submitted for HPS PCR. Cerebrospinal fluids 
from 33 animals were collected for PCR analysis. The cerebrospinal fluids of 4 
animals from Group 1 and one pig from Groups 2, 3 and 4 were not macroscopically 
assessed. Data pertaining to the results from the macroscopic assessment of the 
liquor from these animals including the PCR results were excluded from statistical 
analysis where necessary. Joint capsules and synovial fluids from the left tarsal joint 
were used for HPS PCR analysis. Synovial fluid was not obtained from one pig of 
each tulathromycin group. Furthermore, joint capsules of two pigs from Group 2 were 
also not obtained. Data pertaining to the synovial fluid and the joint capsule from 
these animals were excluded from all statistical analysis. 
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4.2 Clinical results 
4.2.1 Mortalities 
A total of four pigs from each challenged group (44.4% of study animals) were 
removed (death and euthanasia) within 10 days post infection. With the exception of 
two pigs found dead in their pens, all of the animals which were removed were found 
in lateral recumbency and unable to rise. The distribution of the pig deaths per study 
group is shown in Figure 4. None of the control animals were euthanized or died 
before the end of the study on Day 15. Four pigs from Groups 2 and 3 were 
euthanized between Days 2 and 4. One pig from Group 4 was euthanized during this 
time. The remaining 3 pigs from Group 4 were euthanized on Days 6 and 10, with 
one pig found dead on Day 6. There was no significant difference in the time of death 
among the three challenged groups (P=0.15). 
 
Figure 4: Distribution of pig survivals by study group before study termination  
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4.2.2 Clinical examinations 
Examinations for sixteen clinical parameters were performed at two day intervals 
from study day -17 to study termination on Days 14/15. The median total daily clinical 
scores of all four study groups over the course of the study are displayed in Figure 5. 
Pigs with a total daily score up to 4 were classified as clinically healthy and a score of 
4-5 indicated moderate illness. Severe illness was present if the total daily clinical 
score recorded was from 5 to 8. Based on clinical scores throughout the entire study, 
pigs from the control group did not display any signs of clinical illness, and the 
highest clinical score of 4 was recorded on Day -4 for this group. Clinical scores 
indicating severe illness were also seen on Day -4 for pigs from the tulathromycin 7 
day group. Following this day, the total daily clinical score for this group decreased 
below 4 until study day 5. Clinical signs of mild to moderate sickness were seen on 
Days 5, 9, 11 for these pigs. Prior to challenge, scores under 4 were recorded for 
pigs from Groups 2 and 3. After challenge on Day 0, scores indicating severe 
sickness were seen on several days for pigs from the challenged groups. On Day 3, 
pigs from the nontreated-challenged group had a clinical score indicating severe 
illness. Following this peak, the total daily clinical score decreased to 4 until study 
termination on Days14/15. At study termination, scores indicating mild to moderate 
sickness were displayed for pigs from Group 2. The clinical scores of pigs from the 
Group 3 group were below 4 until study day 9 after challenged. On Day 9, scores 
indicating mild illness were observed and then the total score decreased to 4 until 
study termination on Days 14/15. After comparing the clinical scores of all study 
groups, significant differences for the total daily clinical score on any study day 
among the study groups could not be established (P>0.01).  
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Figure 5: Median clinical scores and percentiles according to the study group 
a: 2 pigs from Group 2, 4 pigs from Group 3 and 1 pig from Group 4 were removed from the study; b: 2 pigs from Group 2 were removed; c:1 pig from Group 4 
was removed; d: 2 pigs from Group 4 were removed 
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4.2.3 Average daily gain (ADG)  
Animals from all study groups were weighed on Days -17, 0, 14/15 or when a pig 
died prior to these times. The ADGs including their standard deviations of all pigs 
which survived to study termination (Days 14/15) are shown in Figure 6. A significant 
difference was not seen for the ADGs of pigs during Days -17 and 0. The average 
weight gain of pigs from Group 1 (633.7 g/day) was significantly higher than pigs 
from the challenged groups between Days 0 to 14/15 (P=0.01). Among the 
challenged groups, pigs from Group 2, 3 and 4 had an ADG of 371.3, 478.0 and 
287.3 g/day during the study days 0 and 14/15 respectively. A significant difference 
was not seen among the ADGs of the challenged pigs during Days 0 and 14/15 
(P>0.01). 
 
Figure 6: Average daily gain (g/day) and standard deviations according to study group  
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4.2.4 Rectal temperatures 
The average rectal temperatures for all study groups during the entire study are 
depicted in Figure 7. Rectal temperatures were measured on twelve days over the 
course of the study. At arrival, temperatures of all pigs were between 39.0 °C -
39.3 °C. The rectal temperatures of all study groups on Day -7 were between 39.5-
40.5 °C and remained within this range until Day -1. On Day -1, temperatures of pigs 
from all groups decreased to a range of 39.5 °C -40.1 °C. After challenge on Day 0, 
temperatures rose to 40.2 °C - 41.1 °C in all study groups with the exception of the 
control group. Pigs from the control group had an average temperature of 39.7 °C on 
this day. On Day 3, the temperatures decreased in all groups including temperatures 
of pigs from the control group. With the exception of pigs from Group 4, the rectal 
temperatures of pigs from all groups rose to 40.3 °C on Day 5. The temperatures of 
pigs from the challenged groups continually increased up to Day 7. The rectal 
temperatures of pigs from the control group rose to 39.6 °C on Day 7 and remained 
within this range until Day 11. At study termination, the average rectal temperature of 
pigs from the control group was 39.5 °C. Rectal temperatures of pigs from the 
nontreated-challenged group decreased to 39.5 °C on Day 9 and increased 1 °C for 
the remaining two days. On Day 7, the rectal temperature of pigs from Groups 4 
steadily decreased until study end on Days 14/15. The rectal temperature of pigs 
from Group 3 rose to 40.0 °C on Day 9, decreased on Day 11 and rose once again 
on Day 14/15. The highest temperature from pigs of all study groups before 
challenge was seen on Days -7 and -4. The highest temperatures of pigs from all 
study groups after challenge were seen on Day 1. On Day 7, the second highest 
temperatures for Groups 2 and 4 were observed. A significant difference in the rectal 
temperatures among all challenged groups was not observed (P>0.01). Also, 
significant difference between the control group and the challenged groups was only 
was not observed (P>0.01). 
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Figure 7: Average rectal temperatures according to study group and study day 
4.2.5 Blood examination (Leukocyte population) 
A total of 180 blood samples were collected from pigs of all four study groups on 5 
days during the study (Figure 8). The total number of leukocytes of the Group 1 pigs 
at the first blood collection on Day -1 was 17.4 g/l. A continual decrease in the total 
number of leukocytes was observed for the remaining blood collection days until 
Days 14/15. The leukocyte population of pigs from the control group was 
approximately 13.5 g/l at study termination. A significant difference in the average 
leukocyte cell population of Group 1 pigs for all 5 days was not observed. A 
significant difference between the leukocytes population of the control group and the 
challenged groups was not observed (P=0.012). 
The average leukocyte population of pigs from all challenged groups underwent a 
nearly identical change over the course of the study (Figure 8). A total leukocyte 
population between 19-22.6 g/l was recorded on Day -1. Afterwards, the leukocytes 
population increased to a range of 25.3 - 27.1 g/l on Day 1. Following this increase, 
the leukocyte population of all challenged pigs decreased to a range of 16.41 -
 23.3 g/l up to Day 3. Afterwards, the leukocyte population of all challenged pigs 
increased to a range of 24.5- 35.6 g/l until Day 7. A steady decrease in the leukocyte 
population was observed until study termination on Days 14/15. A comparison of the 
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leukocyte population between the challenged groups demonstrated no statistical 
significance over the course of the entire study (P>0.01). 
 
Figure 8: Average leukocyte numbers (g/l) according to study group and study day 
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4.3 Gross lesions 
4.3.1 Lung assessment 
The average overall percentage of total lung lesions for all pigs without taking time of 
death into consideration is shown in Figure 9. Lung assessment was performed on 
32 lungs from pigs of all four study groups. Lung lesions were not observed in the 
lungs of pigs from the control group and this difference was significant in comparison 
to the challenged groups (P<0.001). On average, fifty percent of the lung lobes of 
pigs from Group 2 displayed macroscopic lesions. Likewise, 47 % and 37.8 % of the 
lung lobes of pigs from Groups 3 and 4 were covered with lung lesions. A significant 
difference among the three challenged groups was not observed (P>0.01). Lesions in 
all pigs were characterized by a dark red mottled appearance and the consistency of 
the lung was firm elastic (Figure 10). Lesions were diffusely spread throughout the 
entire lung parenchyma of all lung lobes. 
 
 Figure 9: Average total lung lesions and standard deviations according to study group  
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Figure 10: Severe lung lesions characterized by a mottled, dark red appearance of lung 
parenchyma 
4.3.2 Synovial fluid assessment 
Synovial fluids were collected from a total of 34 pigs at removal (death or euthanasia) 
or at study termination from all four study groups. The assessment of the synovial 
fluid from each study group is illustrated in Figure 11. Mild and severe changes in the 
synovial fluid of 3 Group 1 pigs were observed. The synovial fluids from the 
remaining 6 pigs were macroscopically unchanged. A significant difference between 
the macroscopic assessment of the synovial fluids of the control and challenged 
animals was not observed (P>0.01). All synovial fluids collected from pigs of Group 2 
were macroscopically changed. Seven pigs from this group had mild synovial 
changes and two pigs had moderate to severe changes. The synovial fluids of one 
pig from Group 3 and three pigs from Group 4 were unchanged. Four pigs from the 
Group 3 had mild synovial changes and the remaining 3 pigs had severely changed 
synovial fluids. Three pigs from the Group 4 day group had mildly changed synovial 
fluid and the remaining two pigs had moderate to severely changed synovial fluid. 
The differences in synovial fluid assessment among the challenged groups were not 
statistically significant (P>0.01).  
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Figure 11: Synovial fluid assessment according to study group 
4.3.3 Cerebrospinal fluid assessment 
A total of 29 cerebrospinal fluids were obtained from pigs of all four study groups. 
The assessment of the cerebrospinal fluid for each study group is displayed in Figure 
12. The cerebrospinal fluids of 3 pigs from each study group were unchanged. The 
remaining 2 pigs of the control group had moderately changed cerebrospinal fluids. 
The cerebrospinal fluids of 5 pigs from Group 2 were severely changed. Five pigs 
from Groups 3 and 4 had mild or severely changed cerebrospinal fluid. The 
differences in cerebrospinal fluid assessment among all study groups were not 
statistically significant (P>0.01).  
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Figure 12: Cerebrospinal fluid assessment of pigs according to study group  
4.3.4 Brain assessment 
The brains of all 36 pigs were assessed at either removal (sudden death, euthanasia) 
or study end and macroscopic changes were not observed in the brains of the pigs 
from the control group (Figure 13). This difference in brain assessment was 
significant between the control pig and pigs from the challenged group (P<0.001). 
The brains of all pigs from Group 3 were macroscopically altered. The brains of 6 
pigs from Group 2 and the brains of 7 pigs from Group 4 were macroscopically 
changed. The brains of 3 pigs from the Group 2 and 2 pigs from the Group 4 were 
macroscopically unchanged. Macroscopic changes in the brain included hyperemia, 
edema and pallor (Figure 14). A significant difference in the brain assessment of pigs 
from all three challenged groups was not observed (P>0.01). 
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Figure 13: Brain assessment according to study group 
                  
Figure 14: Characteristic pathological changes observed after brain assessment (from left to 
right): brain with pallor, edematous and hyperemic brain, brain without pathological changes  
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4.3.5 Assessment of the serosal membranes and cavities 
At necropsy, all grades of inflammation on all serosal surfaces and cavities as 
described in Section 3.5 were seen (Figure 19). Furthermore, hydropericardium, 
hydrothorax, hydroperitoneum including adherences in pleura, pericardium and 
peritoneum were also observed. With the exception of two pigs from Group 1, all 
inflammations were seen in the challenged pigs. These difference between the 
control group and the challenged groups was significant (P<0.01). Pigs from Group 3 
had the most cases of inflammations followed by pigs from Groups 4 and 2, and 
significant difference among the challenged groups was not observed (P>0.01) 
(Figure 15). 
As shown in Figure 16, pleuritis was not observed in any of the pigs from the control 
group, and in four pigs from the nontreated-challenged group. The remaining 5 pigs 
of Group 2 had a severe pleuritis. Pleuritis was also not identified in two pigs from 
Group 3 and five pigs from Group 4. Seven pigs from Group 3 had either a mild or 
severe pleuritis and four pigs from Group 4 had a severe pleuritis. A significant 
difference among all study animals for this inflammation type was not observed 
(P>0.01). 
Results from the assessment of the pericardium are illustrated in Figure 17. 
Pericarditis was not observed in pigs from the control group. Pigs from all challenged 
groups had either no pericarditis or a severe pericarditis. Severe pericarditis was 
seen in 2, 5 and 6 pigs from Groups 2, 3 and 4 respectively. A significant difference 
among all study groups for this inflammation type was not found (P>0.01). The 
results from the peritonitis assessment of all four study groups are depicted in Figure 
18. Two pigs from the control group had a mild peritonitis and the remaining 7 pigs 
did not have any lesions of peritonitis. A significant difference between the control 
pigs and pigs from the challenged group was observed (P<0.01). Mild to moderate 
cases of peritonitis were found in 6 pigs from Group 2. Three pigs from this group 
and two pigs from Group 4 did not have lesions indicative of peritonitis. Six pigs from 
the Group 3 had a mild peritonitis and 3 pigs had a severe peritonitis. A significant 
difference among the challenged groups for the occurrence of the individual 
inflammation type was not established (P>0.01). 
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Figure 15: Total inflammation score according to study group 
 
Figure 16: Average pleuritis scores according to study group 
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Figure 17: Average pericarditis scores according to study group 
 
Figure 18: Average peritonitis score according to study group 
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Figure 19: Severe case of pleuritis, pericarditis and peritonitis observed in challenged pigs at 
necropsy (clockwise from left to right) 
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4.4 Histopathological lesions 
Histopathological examination of all tissue samples mentioned in section 3.6.5 
identified synovitis, pyelitis and meningitis in samples from the challenged pigs. 
Histopathological lesions were not found in any of the tissues samples from pigs of 
the control group (P<0.001). With the exception of 1 pig from Group 3, these findings 
were identified in the challenged pigs which died prior to study termination (Days 
14/15). All other animals including pigs from the control group which died on Days 
14/15 displayed no lesions indicative of an inflammation. The occurrence of the 
individual inflammations is displayed in Table 6. A total of 3 pigs from Group 2 and 4 
pigs Groups 3 and 4 had at least one of the three inflammation types after 
histological assessment. The most frequent inflammation type found was pyelitis, 
which occurred either alone or together with meningitis or synovitis. Similarly, 
meningitis was only identified when a pyelitis or synovitis was present. A significant 
difference for the occurrence of these inflammations among the challenged pigs was 
not observed (P>0.01). 
Table 6: Histopathological examination results according to study group (n= number of 
animals) 
 Pyelitis Synovitis 
Meningitis 
and 
Pyelitis 
Meningitis 
and 
Synovitis 
Meningitis, 
Pyelitis 
and 
Synovitis 
 
  
Control 0 0 0 0 0 n=0 
Nontreated-
challenged 2 0 0 0 1 n=3 
Tulathromycin 
4 day 0 1* 1 0 2 n=4 
Tulathromycin 
7 day 0 0 1 1 2 n=4 
 n=2 n=1 n=2 n=1 n=5  
*Pig euthanized at study termination (Days 14/15) in comparison to all other pigs 
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4.5 PCR detection of HPS genome  
The results of the PCR detection of all 5 sample materials mentioned in section 3.6.6 
are depicted in Table 7. All samples from the control group were negative for HPS 
genome. A total of 129 sample materials were collected from all three challenged 
groups and examined by PCR. HPS genome was detected in at least one of the five 
sample materials of 18 pigs from all three challenged groups. HPS genome was most 
frequently detected in sample materials from pigs of Group 3 followed by pigs from 
Groups 2 and 4. HPS genome was most frequently detected in the collective serosal 
swabs and the cerebrospinal fluid (Table 7). The sensitivity of these two sample 
material types for HPS genome was 44 % and 50 % respectively. HPS genome was 
only detected in the synovial fluids from animals that died at study termination. HPS 
genome was detected in the brains swabs and the collective serosal swabs from 
animals which died prior to study termination. A significant difference for HPS 
detection in the individual sample material was not observed (P>0.05). 
Table 7: PCR results from all five sample materials according to study group, presented as 
number of positive samples 
 
Joint 
capsule 
Synovial 
fluid 
Cerebrospinal 
fluid 
Brain 
swab 
Collective 
serosal 
swab 
 
Control 0 0 0 0 0 n=0 
Nontreated-
challenged 2 1 4 0 4 n=11 
Tulathromycin 
4 day 1 2 3 3 4 n=13 
Tulathromycin 
7 day 2 1 3 1 4 n=11 
 n=5 n=4 n=10 n=4 n=12 n=35 
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4.6 Bacterial isolation of HPS 
Results of the bacterial examinations of the 36 collective serosal swabs are 
presented in Figure 20. All samples from the control group were negative for HPS 
after culture. Positive samples were obtained from the challenged pigs that died prior 
to study termination (Days 14/15). HPS was isolated in four swabs from pigs of 
Groups 2 and 3, and in two collective serosal swabs from pigs of Group 4. A 
significant difference for the frequency of HPS detection among the challenged 
groups was not observed (P>0.01).  
 
Figure 20: Bacterial culture results of the collective serosal swabs according to study group 
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4.7 Association between HPS detection in collective serosal 
swabs by PCR and bacterial culture 
Collective serosal swabs from all 36 animals were tested by both PCR and bacterial 
culture for the presence of HPS genome and HPS respectively. A comparison of the 
HPS detection by PCR and bacterial culture in collective serosal swabs from the 27 
challenged pigs is displayed in Table 8. HPS genome was detected in 12 swabs by 
PCR and in 10 swabs by bacterial culture. HPS was detected by both PCR and 
bacterial culture in 10 swab samples. After statistical analysis, HPS was detected 
equally well by both PCR and bacterial culture (К=0.81). 
Table 8: Frequency of HPS detection by PCR and bacterial examination in collective serosal 
swabs from challenged pigs  
 HPS PCR pos HPS PCR neg  
Bacterial culture 
pos 10 0 n=10 
Bacterial culture 
neg 2 15 n=17 
 n= 12 n=15  
4.8 Associations between HPS detection in samples from 
challenged pigs and clinical results 
4.8.1 Association between HPS detection by PCR and bacterial culture and 
the median total daily clinical score  
Animals with a median total daily clinical score greater than 4 were classified as 
clinically sick and animals with a clinical score lower than four were clinically healthy. 
After challenge, 13 infected pigs showed clinical signs and symptoms indicative of 
mild to severe sickness. HPS genome was detected by PCR in sample materials 
from 9 clinically sick animals and in three sample materials from clinically healthy 
animals (Table 9). After bacterial culture of the collective serosal swabs, HPS was 
detected in swabs from 8 clinically sick animals (Table 10). HPS was significantly 
more frequently detected by PCR (P=0.02) and bacterial culture (P<0.001) in animals 
which had a median total daily clinical score greater than 4 in comparison to pigs with 
a clinical score lower than 4. 
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Table 9: Frequency of HPS genome detection by PCR in samples from challenged pigs and the 
median total daily clinical score 
 
HPS PCR pos pigs HPS PCR neg pigs 
 
Clinical score> 4 9 4 n=13 
Clinical score<4 3 11 n=14 
 
n=12 n=15  
Table 10: Frequency of HPS detection by bacterial culture from collective serosal swabs of 
challenged pigs and the median total daily clinical score 
 
HPS pos pigs- bacterial 
culture 
HPS neg pigs-bacterial 
culture  
Clinical score> 4 8 5 n=13 
Clinical score<4 2 12 n=14 
 
n=10 n=17  
 
 
4.8.2 Association between HPS detection by PCR and bacterial culture and 
time of death 
A total of 12 animals from all three challenged groups were removed (sudden death 
or euthanized) over the course of 10 days after infection. Fifteen challenged pigs 
were euthanized at study termination on Days 14/15. HPS genome was detected by 
PCR in at least one of the five sample materials collected from the 12 pigs which died 
or were euthanized before study end and in samples from six pigs which died at 
study termination (Table 11). HPS was detected by bacterial culture in collective 
serosal swabs from 10 pigs and all samples were from pigs which died prior to study 
termination (Table 12). HPS was detected significantly more frequently by PCR 
(P<0.001) and bacterial culture (P<0.001) in samples from animals that died prior to 
study end in comparison to samples from animals which died at study termination.
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Table 11: Frequency of HPS genome detection by PCR in samples from challenged pigs which 
died prior to and a study termination  
 HPS PCR pos pigs HPS PCR neg pigs  
Pigs dead before 
study end 12 0 n=12 
Pigs dead at study 
end 6 9 n=15 
 n= 18 n=9  
Table 12: Frequency of HPS detection by bacterial culture in samples from challenged pigs 
which died prior to and a study termination  
 
HPS pos pigs- 
bacterial culture 
HPS neg pigs- 
bacterial culture  
Pigs dead before 
study end 10 2 n=12 
Pigs dead at study 
end 0 15 n=15 
 n= 10 n=17  
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4.9 Association between HPS detection in samples from 
challenged pigs and gross lesions  
4.9.1 Association between HPS detection in collective serosal swabs and the 
total inflammation score 
If an animal had a total inflammation score greater than 6, a polyserositis was 
assumed to present. From 27 challenged pigs, polyserositis was seen in a total of 17 
pigs from all three challenged groups. Polyserositis was not observed in pigs from 
the control group. HPS genome was detected by PCR in the collective serosal swabs 
from 11 pigs which had a polyserositis and in 1 sample from a pig which did not have 
a polyserositis (Table 13). After the bacterial culture, HPS was identified in the 
collective serosal swabs from 10 animals which had a polyserositis (Table 14). HPS 
was detected more frequently by PCR (P=0.01) and bacterial culture (P<0.001) in 
collective serosal swabs from animals with a polyserositis than in samples from 
animals without a polyserositis. 
Table 13: Frequency of HPS genome detection by PCR in collective serosal swabs from 
challenged pigs and the occurrence of polyserositis 
 PCR HPS pos PCR HPS neg  
Polyserositis present 11 6 n=17 
Polyserositis absent 1 9 n=10 
 n=12 n=15  
Table 14: Frequency of HPS identification by bacterial examination in collective serosal swabs 
from challenged pigs and the occurrence of polyserositis 
 
Bacterial culture 
HPS pos 
Bacterial culture HPS 
neg  
Polyserositis present 10 7 n=17 
Polyserositis absent 0 10 n=10 
 
n=10 n=17  
Results  71 
4.9.2 Association between HPS detection in collective serosal swabs and 
pleuritis, pericarditis, and peritonitis 
With the exception of two pigs from the control group, all three inflammation types 
were observed in pigs which were infected with HPS. As shown in Figure 21, HPS 
genome was detected by PCR in the collective serosal swabs of 11, 7 and 9 pigs that 
had a pleuritis, pericarditis and peritonitis respectively. HPS genome was also 
detected in a swab sample from 1 animal that did not have lesions of pleuritis and in 
samples from 5 animals which did not have either a pericarditis or peritonitis. After 
bacterial culture, HPS was isolated in the swabs from 10, 6 and 8 pigs which had 
pleuritis, pericarditis and peritonitis respectively (Figure 22). HPS was also found in 
swabs from 4 pigs that did not have a pericarditis and 2 pigs which did not have 
peritonitis. HPS genome was significantly more frequently detected by PCR in 
samples from animals that had a pleuritis (P<0.001) and peritonitis (P=0.03) than 
animals without these two inflammation types. Similarly, HPS was isolated more 
frequently by bacterial culture in samples from animals that had a pleuritis (P<0.001) 
and peritonitis (P<0.001). An association between the positive identification of HPS 
genome in the collective serosal swab by either PCR or bacterial culture and the 
occurrence of pericarditis was not observed (P>0.05). 
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Figure 21: Frequency of HPS genome isolation by PCR in collective serosal swabs from 
challenged pigs and the occurrence of pleuritis, pericarditis and peritonitis 
Figure 22: Frequency of HPS detection by bacterial culture in collective serosal swabs from 
challenged pigs and the occurrence of pleuritis, pericarditis, and peritonitis 
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4.9.3 Association between HPS genome detection in cerebrospinal fluids, 
brain swabs and the assessment of the brains and cerebrospinal fluids 
The brains of 22 pigs from all challenged groups were macroscopically changed. 
Cerebrospinal fluids from 24 challenged pigs were macroscopically examined and 
mild to severe changes in samples from 15 challenged pigs were observed. HPS 
genome was detected by PCR in the brain swabs of 4 pigs whose cerebrospinal fluid 
and brains were macroscopically altered (Figure 23). Also, HPS genome was 
detected in the brain swabs from 4 pigs whose cerebrospinal fluids were 
macroscopically changed (Figure 24). HPS genome was detected in the 
cerebrospinal fluids from 6 pigs whose brains were macroscopically changed. Also, 
HPS genome was detected in the cerebrospinal fluids from 4 pigs whose brains were 
macroscopically unchanged (Figure 25). In addition, HPS genome was detected in 
the cerebrospinal fluids of 7 pigs whose cerebrospinal fluids were macroscopically 
altered and in 2 pigs whose cerebrospinal fluids were macroscopically unchanged 
(Figure 26). A significant association was not found between the frequency of HPS 
genome detection in brain swabs and cerebrospinal fluids and the macroscopic 
assessment of the brain and cerebrospinal fluid (P>0.05). 
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Figure 23: Frequency of HPS genome detection by PCR in the brain swabs from challenged 
pigs and the assessment of the brain  
Figure 24: Frequency of HPS genome detection by PCR in the brain swabs from challenged 
pigs and the assessment of the cerebrospinal fluids 
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Frequency of HPS genome detection in cerebrospinal fluids by PCR and the 
assessment of the brain
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Figure 25: Frequency of HPS genome detection by PCR in cerebrospinal fluids from challenged 
pigs and the assessment of the brain  
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Figure 26: Frequency of HPS genome detection by PCR in cerebrospinal fluids from challenged 
pigs and the assessment of the cerebrospinal fluids 
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4.9.4 Association between HPS genome detection in synovial fluids, joint 
capsules and the synovial fluid assessment 
The synovial fluids of 25 challenged pigs were macroscopically examined and mild to 
severe changes were seen in samples from 21 pigs. A total of 25 joint capsules and 
synovial fluid samples were obtained from all 27 challenged animals for HPS PCR 
testing. HPS genome was detected in the synovial fluids of 3 pigs whose synovial 
fluids were macroscopically altered (Table 15). In addition, HPS genome was 
detected in the synovial fluid from 1 pig whose synovial fluid was macroscopically 
unchanged. Also, HPS genome was found in the joint capsules of 5 pigs whose 
synovial fluids were macroscopically altered (Table 16). A corresponding 
identification of HPS genome in both joint capsule and synovial fluid was not 
observed. A significant association was not found between the frequency of HPS 
genome detection in the joint capsule and synovial fluid and the macroscopic 
assessment of the synovial fluid (P>0.05). 
Table 15: Frequency of HPS genome detection by PCR in synovial fluids from challenged pigs 
and the assessment of the synovial fluid 
 
HPS PCR pos-
synovial fluid 
HPS PCR neg-
synovial fluid  
Synovial fluid 
changed 3 18 n=21 
Synovial fluid 
unchanged 1 3 n=4 
 
n=4 n=21  
Table 16: Frequency of HPS genome detection by PCR in joint capsules from challenged pigs 
and the assessment of the synovial fluid 
 
HPS PCR pos-joint 
capsule 
HPS PCR neg-joint 
capsule  
Synovial fluid 
changed 5 14 n=19 
Synovial fluid 
unchanged 0 4 n=4 
 
n=5 n=18  
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4.10 Association between HPS detection in samples from 
challenged pigs and histopathological lesions 
4.10.1 Association between HPS genome detection in synovial fluids and joint 
capsules and synovitis  
After microscopic examination, synovitis was observed in tissue samples from 7 
challenged pigs. A total of 25 joint capsules and synovial fluid samples were obtained 
from the 27 challenged animals for HPS PCR diagnostic. HPS genome was detected 
in the joint capsules of 2 pigs with a synovitis and also in the capsules of 3 pigs 
without synovitis (Table 17). Additionally, HPS genome was detected in the synovial 
fluids of 4 pigs without a synovitis (Table 18). A corresponding detection of HPS 
genome in both the synovial fluid and the joint capsule was not observed. A 
significant association was not seen between the frequency of HPS genome 
detection in the joint capsule and the synovial fluid and the occurrence of synovitis 
(P>0.05). 
Table 17: Frequency of HPS genome detection by PCR in the joint capsules from challenged 
pigs and the occurrence of synovitis 
 
HPS PCR pos-joint 
capsule 
HPS PCR neg-joint 
capsule  
Synovitis present 2 5 n=7 
Synovitis absent 3 15 n=18 
 
n=5 n=20  
Table 18: Frequency of HPS genome detection by PCR in the synovial fluids from challenged 
pigs and the occurrence of synovitis 
  
HPS PCR pos- 
synovial fluid 
HPS PCR neg- 
synovial fluid  
Synovitis present 0 7 n=7 
Synovitis absent 4 14 n=18 
 
n=4 n=21  
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4.10.2 Association between HPS genome detection in cerebrospinal fluids and 
brain swabs and meningitis 
After histopathological examination of tissues from the 27 challenged pigs, mild to 
severe meningitis was observed in 7 pigs from all three challenged groups. A total of 
27 brain swabs and 25 cerebrospinal fluid samples were collected from pigs of all 
challenged groups for PCR testing. HPS genome was detected in the cerebrospinal 
fluid of 6 pigs with meningitis and in samples from 4 pigs which did not have 
meningitis (Table 19). Furthermore, HPS genome was detected in the brain swabs of 
4 pigs which had meningitis (Table 21). HPS was significantly more frequently 
detected in the cerebrospinal fluids (P<0.001) and the brain swabs (P<0.001) of 
animals with meningitis than in animals without meningitis. 
Table 19: Frequency of HPS genome detection in cerebrospinal fluids from challenged pigs 
and the occurrence of meningitis 
 
HPS PCR pos- 
cerebrospinal fluid 
HPS PCR neg- 
cerebrospinal fluid  
Meningitis present 6 0 n=6 
Meningitis absent 4 15 n=19 
 
n=10 n=15  
Table 20: Frequency of HPS genome detection in brain swabs from challenged pigs and the 
occurrence of meningitis 
 
HPS PCR pos- brain 
swab 
HPS PCR neg- brain 
swab  
Meningitis present 4 3 n=7 
Meningitis absent 0 20 n=20 
 
n=4 n=23  
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4.10.3 Association between HPS detection and pyelitis 
Pyelitis was identified in tissue samples of 10 pigs from all three challenged groups. 
A total of 129 sample materials and 27 serosal swabs were collected for HPS PCR 
and bacterial examination respectively. HPS genome was detected by PCR in at 
least one of the five sample materials from the 10 pigs which had a pyelitis (Table 
21). Additionally, HPS genome was also found in samples from 2 pigs which did not 
have a pyelitis after histopathological examination. Following bacterial culture, HPS 
was isolated in 8 collective serosal swabs from pigs with pyelitis and also in 2 
samples from pigs without pyelitis (Table 22). A corresponding identification of HPS 
by both PCR and bacterial culture was seen in samples from 8 pigs with pyelitis. HPS 
was significantly more frequently detected by PCR (P<0.001) and bacterial culture 
(P<0.001) in challenged pigs which had a pyelitis than in samples from animals 
without a pyelitis. 
Table 21: Frequency of HPS genome detection by PCR in samples from challenged pigs and 
the occurrence of pyelitis  
 
HPS PCR pos HPS PCR neg  
Pyelitis present 10 0 n=10 
Pyelitis absent 2 15 n=17 
 n=12 n=15  
Table 22: Frequency of HPS detection bacterial culture in collective serosal swabs from 
challenged pigs and the occurrence of pyelitis  
 
HPS PCR pos- 
bacterial culture 
HPS PCR neg- bacterial 
culture  
Pyelitis present 8 2 n=10 
Pyelitis absent 2 15 n=17 
 
n=10 n=17  
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5 Discussion 
5.1 Clinical results 
5.1.1 Mortalities 
The HPS challenge model used in this study produced peracute, severe clinical signs 
which resulted in the removal (death or euthanasia) of four pigs from each 
challenged group within ten days post infection. The high number of deaths 
corresponds with the findings of previous studies about the highly pathogenic nature 
of HPS serovar 5. According to RAPP-GABRIELSON et al. (2006), serovar 5 is highly 
virulent capable of eliciting death in pigs. Similarly, other authors reported the deaths 
of several pigs shortly after experimental infection with HPS serovar 5 (AMANO et al., 
1997; BAK and RIISING, 2002; DE LA FUENTE et al., 2008b). Serovar 5 was 
selected for this study since it is one of the most prevalent serovars affecting swine 
producers in Germany and therefore suitable for testing the efficacy of tulathromycin 
(KIELSTEIN et al., 2001; RAPP-GABRIELSON et al., 2006). 
The timing of these the deaths, however, differed numerically but not statistically 
between the individual study groups. Four pigs from the nontreated-challenged and 
tulathromycin 4 day groups died within four days after challenge. In contrast, only 
one pig from the tulathromycin 7 day group died during this time. The remaining 3 
pigs from this group died between days 6 and 10. HOOVER (2009) investigated the 
efficacy of tulathromycin in weaned pigs over a 56-day period and found that 
mortality rates were significantly lower in tulathromycin-treated pigs than pigs which 
did not receive tulathromycin. Likewise, NUTSCH et al. (2005) reported significantly 
lower mortality rates in feeder pigs with swine respiratory disease including HPS 
which received tulathromycin. In these and other tulathromycin studies, the 
therapeutic efficacy of tulathromycin was assessed based on either reports from field 
studies or based on experimental infection where tulathromycin was always 
administered directly after infection with HPS (EVANS, 2005; NANJIANI et al., 2005). 
This is the first challenge study which investigates the efficacy of tulathromycin in 
pigs which were infected after treatment. 
It could be inferred from these study results that an antimicrobial effect of 
tulathromycin was present which may have prolonged the lethal effects of the serovar 
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5 in both tulathromycin groups. Currently, 2.5 mg/kg BW is the only registered dose 
for tulathromycin application in pigs. This dose was selected for the study since it 
corresponds to the present dose that swine producers are currently using, and is the 
dose proven to be effective in extensive laboratory and field trials against a variety of 
pathogens including HPS. Another reason for the apparent absence of a significant 
antimicrobial effect may be that the HPS strain used in this study was resistant 
towards tulathromycin. However, the results of the MIC test showed that the HPS 
serovar 5 strain used in this study was susceptible towards tulathromcyin (MIC 500 
µg/l). NANJIANI et al. (2005) determined that the MIC of various HPS strains of 
swine farms from four European countries was 4 µg/ml. The differences in challenge 
strain MIC compared to the pan-European survey values may be due to the fact that 
either the HPS strains or serovars used in this study were not identical to those 
tested by NANJIANI et al. The application of the relatively high inoculum dose 
intratracheally may have overcome any significant antimicrobial effect. According to 
AMANO et al. (1997), an organism inoculated intratracheally circumvents the 
mucosal immunity of the upper respiratory tract and can cause systemic infection 
more easily. Thus an antimicrobial effect may have existed but due to the high dose 
and intratracheal application, a significant antimicrobial effect was not observed. 
Furthermore, the administration time of tulathromycin may have been unsuitable for 
this challenge model. After intramuscular application, the plasma concentration of 
tulathromycin is 0.58 µg/ml. In contrast, the lung concentrations are up to 181 times 
higher than the plasma concentration (EVANS, 2005). The lung-half life time of 
tulathromycin is 6 days. Therefore, an application of tulathromycin seven and four 
days prior to infection means that only half of the active ingredient is available to 
protect the pig against septicemic spread. Further studies are necessary to confirm 
the results observed in this study.  
5.1.2 Clinical examinations  
In this study, in addition to high mortalities, all characteristic clinical signs indicative of 
Glässer’s disease were observed within 48 hours after challenge. Generally, there 
are a number of pathogens which can elicit clinical signs similar to HPS infection 
such as Mycoplasma hyorhinis. Screening of all study animals prior to and during the 
study showed that all animals were negative for HPS, Mycoplasma hyorhinis and 
Actinobacillus pleuropneumoniae. Based on the clinical scores throughout the entire 
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study, pigs from the control group did not display signs of clinical illness and the 
highest clinical score of 4 was recorded on Day -4 for this group. On this particular 
day, a median clinical score of 6 indicating severe sickness were seen in pigs from 
the tulathromycin 4 group. As demonstrated in the following days leading up to the 
challenge day (Day 0), clinical scores indicating that all 36 pigs were clinically healthy 
were recorded. Since an infection was not present in any of the pigs before the 
scheduled infection on Day 0 and screening results indicated that all pigs were 
clinically healthy until challenge Day 0, this peak may have been due to higher 
scoring in parameters such as sclera or conjunctiva appearance for a few pigs which 
subsequently led to an overall high total daily clinical score for that day. Furthermore, 
a clinical score of four was recorded for this group partly because this was an 
infection of commercial pigs and not an infection of gnotobiotic animals. Previous 
HPS experimental studies predominantly used either SPF animals or gnotobiotic pigs 
(AMANO et al., 1997; BLANCO et al., 2008; OLIVEIRA et al., 2003a). Following 
challenge on Day 0, animals from the challenged groups displayed severe clinical 
symptoms from all 16 parameters mentioned in the material and methods section. 
Although significant differences among the three challenged groups were not found, 
differences in the severity and occurrence of the sickness were evident among the 
challenged groups. Pigs from the nontreated-challenged group were the first to 
showed signs of mild to severe sickness in comparison to pigs from the tulathromycin 
groups. High scores were recorded up to study day 5 for this group. Meanwhile 
scores indicating mild to moderate illness were seen in both tulathromycin groups 
from study day 5 to study day 11. Within the first four days after challenge, 4 pigs 
from the nontreated-challenged group displayed symptoms of severe illness which 
led to the death or removal of these pigs. The score from these pigs influenced the 
overall total daily clinical score for that group hence the peaks until all four pigs and 
their clinical data were removed from the study after Day 4. During this time, the 
same number of deaths was reported only from pigs of the tulathromycin 4 day 
group. Only one pig died from the tulathromycin 7 day group during this time. 
Therefore, these pigs with clinical scores indicating sickness, survived longer and 
subsequently influenced the overall total daily clinical score of their respective groups 
until these pigs along with their data were also excluded from the study on Day 10. 
Hence the longer display of high clinical scores as seen in Figure 5 until Day 10 for 
both tulathromycin groups.  
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OLIVEIRA and PIJOAN (2002) found that the severity of clinical signs depended not 
only on the virulence of the strain but also on the immune status of the pig and the 
current stage of infection. In this study, a relatively high infection dose (5 x108 CFU) 
was used to infect the pigs. According to OLIVEIRA et al. (2003a), the ideal dose 
used for reproduction of HPS infections depends on the characteristics of the aims of 
the study. Depending on the dose, either a colonization of the pig is achieved or the 
manifestation of clinical signs of disease. In order to test the efficacy of tulathromycin, 
the manifestation of clinical signs in the pigs were required for this study. The clinical 
signs manifested in the pigs without taking treatment into consideration correspond to 
the findings of other experimental studies. OLIVEIRA et al. (2003a) found that 
animals inoculated with 108 to 109 CFU developed systemic infections compared with 
animals inoculated with a lower dose such as 106 to 107 CFU. After infecting SPF 
piglets with 106 to 109 HPS serovar 5, BLANCO et al. (2008) found that piglets 
displayed symptoms of severe illness such as dyspnoea, cyanosis, lameness and 
central nervous impairment. Similarly, SEGALES et al. (1999) and MACINNES et al. 
(2003) observed severe clinical symptoms such as lethargy, recumbency and even 
sudden death in infected pigs shortly after infection with 107 CFU HPS serovar 5.  
Notwithstanding this apparent success of the infection model, a significant difference 
between the nontreated-challenged pigs and the pigs receiving tulathromycin was not 
observed. In pigs treated with therapeutically with tulathromycin, the overall cure rate 
was significantly higher in comparison to cure rates of pigs which did not receive 
tulathromycin (NUTSCH et al., 2005). NANJIANI et al. (2005) found that the severity 
of clinical symptoms were lower in the tulathromycin–treated animals than animals 
without tulathromycin. Similarly, clinical symptoms were significantly lower in 
tulathromycin-treated pigs over a 56-day study period than pig which did not receive 
tulathromycin (HOOVER, 2009). As mentioned previously, these studies tested 
tulathromycin under field conditions or in experimental studies whereby tulathromycin 
administration occurred directly after the infection. Factors such as too high inoculum 
dose or the untimely application of tulathromycin may have hindered tulathromycin 
from preventing the septicemia spread and thus the severe clinical symptoms seen in 
both tulathromycin treated groups. 
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5.1.3 Average daily gain (ADG) 
The average daily weight gains of pigs from all groups before challenge (Days-17 to 
0) were comparable and a significant difference among the groups was not observed. 
In contrast, the average daily weight gains of pigs from all groups between Days 0 to 
14/15 varied widely. The average daily gains of pigs from the control group were 
higher than the ADGs of pigs from the challenged groups between Days 0 to 14/15 
but a significant difference could not be established. The low weight gains seen in all 
challenged pigs in comparison to the control pigs corresponds to the total daily 
clinical score for these animals observed over the course of the study. Mild to severe 
illness were seen in all challenged pigs, and therefore a subsequent decrease in 
body weight or slow weight gain is expected in animals that are sick. 
Only pigs from the tulathromycin 4 day group had an ADG comparable to the ADGs 
of the control group. Similarly, the third highest average daily gain between Days 0 to 
14/15 was recorded by pigs from the nontreated-challenged. Pigs from the 
tulathromycin 7 day group had the lowest ADGs from all challenge groups during this 
period. On European farms infected with pathogens of the swine respiratory disease 
complex such as HPS, NANJIANI et al. (2005) found that pigs administered different 
doses of tulathromycin did not show any significantly improved ADG in comparison to 
pigs which did not receive tulathromycin. Conversely, HOOVER (2009) investigated 
the efficacy of tulathromycin against swine respiratory disease including HPS and 
found that tulathromycin treated animals gained significantly more weight than pigs 
which did not receive tulathromycin. In contrast to this present study, both studies 
tested the efficacy of tulathromycin in pigs which were not only sick with an 
unverifiable amount of HPS but also infected with other swine pathogens. Since pigs 
from the tulathromycin 4 day group had the best ADG’s from all challenged pigs, an 
antimicrobial effect may have been present. However, an explanation as to why pigs 
from the tulathromycin 7 day group had worse ADGs in comparison to the ADGs of 
the nontreated-challenged pigs remains to be determined. Further investigations are 
necessary to confirm these results. 
5.1.4 Rectal temperatures 
The rectal temperatures of pigs from all study groups were relatively high for the 
entire study period and a significant difference among the four study groups was not 
seen either prior to or after challenge. Nevertheless, peak temperatures were seen 
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one day before challenge on Day -7, and on Days 1 and 7 directly after challenge. 
According to STRAW et al. (2008), the rectal temperatures of healthy pigs between 
9-45 kg ranges between 39.3 °C and 39.0 °C respectively. It is most likely that the 
septicemic spread of HPS in the pigs resulted in fever which was responsible for the 
peak temperatures seen on Days 1 and 6 in challenged pigs. SOLANO et al. (1997) 
reported pronounced but not significant rectal temperatures differences among 
challenged and control pigs one day after infection with HPS. Similarly, DE LA 
FUENTE et al. (2009) and VAHLE et al. (1995) observed a mild transient rise in 
rectal temperature between 40.0 °C and 40.5 °C directly after challenge with HPS. 
Screening results of all pigs prior to and after challenge indicated that all animals 
were healthy until infection with HPS on challenge day 0; therefore, some other factor 
must have influenced the rectal temperature measurements of the pigs before HPS 
infection. Furthermore, extreme variations in the temperatures of all pigs over the 
course of the study were observed. The extremely high and fluctuating temperatures 
observed throughout this study were most likely due to the manual restraint of the 
pigs and not solely the result of the HPS challenge. In order to measure the rectal 
temperature and assess the synovial fluid in each joint, every animal was manually 
restrained by at least one assisting veterinarian in this study. While under restraint, 
the pigs struggled and made several attempts to escape. Various authors 
demonstrated that pigs are very susceptible to stress and manual handling in pigs is 
associated with an extreme stress reaction which leads to elevated cortisol levels 
and rectal temperatures (MADEJ et al., 1996; ROOZEN et al., 1995). 
5.2 Blood examination (Leukocyte population) 
The course of the average leukocyte population of the four study groups differed 
throughout the study. Since the control pigs were not infected with HPS, an increase 
in the leukocyte population was not expected. In contrast, the leukocyte population of 
the challenged animals was notably higher than the leukocyte population of the 
control animals. According to FRIENDSHIP et al. (1984), the reference value for the 
leukocyte count in weaned piglets is 8.7 - 37.9 x 109 cells/L. Elevated leukocyte 
populations were seen one day directly after challenge. This corresponds to the short 
incubation time of 24 hours reported by DE LA FUENTE et al. (2008b) after 
experimental infection with HPS serovar 5 in weaned piglets. After this rise in 
leukocyte numbers, the number of leukocytes decreased on Day 3, then gradually 
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rose up to Day 7 and finally decreased until study termination. HEINRITZI (2006) 
described a similar course of the leukocyte population after HPS infection. However, 
AMANO et al. (1997) observed a severe leucopenia 24 hours after challenge until 
death. 
Contrary to the expectations of this study, a significant difference between the 
leukocyte population of the tulathromycin groups and the untreated-challenge group 
was not observed. Only pigs from the tulathromycin 4 day group had lower leukocyte 
populations in comparison to pigs from the nontreated-challenged group. Pigs from 
the tulathromycin 7 day group had the highest leukocyte populations during the entire 
study. For reasons previously discussed, apparently the tulathromycin administration 
was unable to significantly prevent or lessen the septicemic spread of the disease in 
the tulathromycin groups which led to the dramatic increase in the leukocyte 
population. 
5.3 Gross lesions 
5.3.1 Lung lesions 
Lung lesions indicative of pneumonia were seen in the lungs of pigs from all three 
challenged groups. As expected, no lung lesions were observed in the lungs of pigs 
from the control group. According to SOLANO-AGUILAR et al. (1999) and 
RITZMANN and HEINRITZI (2005), gross lesions of Glässer’s disease are 
characterized by a catarrhal-purulent bronchopneumonia. OLIVEIRA and PIJOAN 
(2002) found that pneumonia is characterize by antero-ventral consolidation with 
purulent exudate in the bronchi and bronchioli. Moreover, DE LA FUENTE (2008a) 
found lesions of exudative pneumonia with alveolar edema and hyperemia in the 
cranial lung lobes of HPS experimentally infected weaned piglets. In this study, 
lesions in all pigs were diffusely spread throughout the entire lung parenchyma of all 
lung lobes. A consolidation of an individual lung lobe was not observed. The lack of a 
purulent component in the lung lesions most likely indicates an early infection stage 
in the pigs. 
Although the lungs of pigs from the nontreated-challenged group showed the most 
lung lesions, a significant difference among the three challenged groups was not 
observed. Based on the pharmacokinetic properties of tulathromycin, fewer lung 
lesions were expected in the pigs that received tulathromycin in comparison to the 
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nontreated-challenged pigs. According to BENCHAOUI et al. (2004) the high 
distribution and slow elimination following a single dose of tulathromycin are 
desirable pharmacokinetic properties for an antibiotic indicated for the treatment of 
respiratory disease in swine. In a study evaluating the therapeutic activity of 
tulathromycin against pathogens of the swine respiratory disease complex on farms 
in Europe, NANJIANI et al. (2005) found that pigs treated with tulathromycin showed 
better clinical improvements in comparison to pigs without tulathromycin. The same 
author noted that the improvement lasted at least 10 days after treatment. Similarly, 
NUTSCH et al. (2005) and HOOVER (2009) found that a single intramuscular dose 
of tulathromycin was effective in the treatment of swine respiratory disease. 
Furthermore, in studies evaluating the efficacy of tulathromycin for the treatment of 
pneumonia following experimental infection of swine with Mycoplasma 
hyopneumoniae, STANFORD (2008) and MCKELVIE et al. (2005) found that 
tulathromycin was effective in the treatment of pneumonia.  
After intramuscular injection, tulathromycin has a high bioavailability (88 %) and 
achieves concentrations in the lungs which are significantly higher than plasma 
concentrations (EVANS, 2005). Moreover, tulathromycin has a lung half-life of 6 days 
(BENCHAOUI et al., 2004; NOWAKOWSKI et al., 2004). This long half-life in lung 
tissues means that the drug concentrations are at therapeutic levels for several days, 
increasing the exposure time of pathogens such as HPS to tulathromycin and thus 
possibly optimizing the antibacterial activity. Therefore, in the case of the pigs which 
received tulathromycin seven and four days prior to HPS infection, the maximum 
active ingredient concentration possible to prevent septicemic spread was not 
present. It is also possible that the intratracheal administration of the relatively high 
challenge inoculums dose was sufficient to overcome any antimicrobial effect of 
tulathromycin in the lung thus resulting in lung lesions in pigs from both treatment 
groups. Another explanation for the study results may be due to the infection route 
used. According to AMANO et al. (1997), an organism inoculated intratracheally 
circumvents the mucosal immunity of the upper respiratory tract, and can cause 
systemic infection more easily. Also, if the intratracheal application is performed 
incorrectly, the tracheal catheter can enter the lung lobe and significantly damage 
lung tissue while doing so. Furthermore, various authors noted that pathogens of the 
oropharyngeal cavity such as Streptococcus suis and Escherichia coli could enter the 
lungs if the tracheal catheter comes in contact with the mucous membrane or tonsils 
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(GANTER et al., 1993; HENNIG-PAUKA et al., 2007; KIPPER, 1990). These 
additional pathogens could compound the pathogen level which the tulathromycin 
would have to work against.  
5.3.2 Synovial fluid assessment 
Pathological changes in the synovial fluids were seen in all pigs from each study 
group including the control pigs. However, the synovial fluids of pigs from the control 
group were less pathologically changed in comparison to the fluids from the 
challenged pigs. Since the control pigs were not infected with HPS, it is assumed that 
a noninfectious source such as blunt trauma was responsible for the synovial 
changes observed in this group. Severe changes in appearance and/or content 
implies a fibrinous to fibrinopurulent inflammatory process in the joint. The synovial 
fluid changes seen in the challenged pigs without taking treatment into consideration 
are consistent with findings from other HPS experimental studies. After infection of 
both colostrum-deprived and sow-reared piglets with HPS serovar 5, more than half 
of the animals had distended joint capsules (BLANCO et al., 2004). DE LA FUENTE 
(2008a) found that the joints were distended by variable amounts of fibrinopurulent 
exudates. Similarly, SOLANO-AGUILAR et al. (1998) noted that some of the infected 
pigs had swollen joints due to fibrinous exudate. Comparable results were also 
reported by VAHLE et al. (1995). This author found that the carpal joints were 
covered by variable amounts of fibrinopurulent exudate which often extended into 
adjacent periarticular soft tissues and fascial planes. 
Although a significant difference among the groups was not found, the synovial fluids 
obtained from the nontreated-challenged pigs were all pathologically altered in 
contrast to fluids from pigs of both tulathromycin groups. Furthermore, synovial fluid 
from pigs of the tulathromycin 7 day group had the least amount of pathological 
changes. A literature survey did not yield any information about pharmacokinetic 
properties of tulathromycin in the joint. Due to the fact that mild to severe changes in 
the synovial fluids were seen in tulathromycin treated pigs, a significant antimicrobial 
effect of tulathromycin is possible. It is possible that tulathromycin may have been 
present in the joint but in too low concentrations to elicit a significant antimicrobial 
effect to prevent synovial fluid changes. Tulathromycin has the pharmacodynamic 
property of accumulating in blood polymorphonuclear leukocytes or neutrophils 
(SIEGEL et al., 2004). Thus pigs which receive tulathromycin earlier, in this case the 
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tulathromycin 7 day pigs, would subsequently have high plasma concentrations of 
tulathromycin. Further investigations are necessary to confirm these observations.  
5.3.3 Cerebrospinal fluid assessment 
The cerebrospinal fluid was assessed based on the same criteria used for the 
synovial fluid assessment. Pathological changes in the cerebrospinal fluids were 
seen in samples from all four study groups. However, the severity of the changes 
differed significantly among the groups. Mild pathological changes in the 
cerebrospinal fluids from two control pigs were seen. These changes are probably 
due to a noninfectious origin since screening results showed that the pigs were 
clinically healthy and not infected with HPS. Moreover, the corresponding brain 
assessments demonstrated that the brains were pathologically unchanged. In 
contrast to the results from the control pigs, moderate to severe pathological changes 
in the cerebrospinal fluids were seen in 5 pigs from each challenge group. A detailed 
description of cerebrospinal fluid assessment by an HPS infection in the literature is 
very seldom. Based on previous studies, characteristic gross pathological lesions by 
HPS infection include all stages of meningitis (BLANCO et al., 2004; DE LA FUENTE 
et al., 2008a; MACINNES and DESROSIERS, 1999). It can be assumed that 
meningitis is accompanied by corresponding changes in the cerebrospinal fluid. 
Although pathological changes were seen in the cerebrospinal fluids from 5 pigs from 
all challenged groups, pigs from the nontreated-challenged group had the most 
cases of pathologically changed cerebrospinal fluid. This improvement in the fluids of 
the tulathromycin group may be attributed to tulathromycin. However, there exist no 
current literature about the pharmacokinetic properties of tulathromycin and its 
influence on the central nervous system. Further investigations are necessary to 
confirm the results seen in this study. 
5.3.4 Brain assessment 
Pathological changes in the brains were only observed in the challenged pigs. Since 
the control pigs were not challenged and the screening results indicated that these 
pigs were healthy, pathological changes were not expected. Changes seen consisted 
primarily of hyperemia, edema and pallor. DE LA FUENTE et al. (2008b) found that 
the brains of HPS infected weaned piglets were hyperemic with petechiae or 
echymoses. Similarly observations were also made by AMANO et al. (1994) after the 
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inoculation of pigs with HPS serovars 1, 4, and 5. Although petechiae or ecchymoses 
were not seen in this study, the macroscopic observations after the brain assessment 
are consistent with the results from previous experimental HPS studies. 
In contrast to pigs from the nontreated-challenged and tulathromycin 7 day groups, 
the brains of pigs from the tulathromycin 4 day group were all pathologically 
changed. Only 6 pigs from the nontreated-challenged group and 7 pigs from the 
tulathromycin 7 day group had pathological brain changes. Due to the fact that even 
the tulathromycin pigs had brain lesions, a significant antimicrobial effect of the 
tulathromycin treatment cannot be established. As mentioned in the previous section, 
the pharmacokinetic properties of tulathromycin and its effect on the central nervous 
system have yet to be determined. Further studies are necessary to confirm the 
observations made in this study.  
5.3.5 Assessment of serosal membranes and cavities  
According to RITZMANN and HEINRITZI (2005), HPS has a clear affinity to serosal 
surfaces, and bacteremia follows replication at serosal surfaces which subsequently 
produces the characteristic polyserositis observed in pigs (AMANO et al., 1994; 
VAHLE et al., 1995). After challenge, polyserositis was observed in several pigs from 
all the challenged groups, and pigs from the tulathromycin 4 day group had the most 
cases of inflammations followed by pigs from the tulathromycin 7 day and 
nontreated-challenged groups. Moreover, adherences in pleura, pericardium, and 
peritoneum including hydrothorax, hydropericardium and hydroperitoneum were also 
seen. In previous studies by BLANCO et al. (2004) and BAK and RIISING (2002) 
severe polyserositis and adherences in the serosal cavities after experimental 
infection with HPS were observed. Similarly, SOLANO-AGUILAR et al. (1999) found 
that severe serositis was consistently observed in most HPS infected pigs. 
All three inflammation types were seen in pigs from all study groups. However, the 
severity of the individual inflammations pleuritis, pericarditis and peritonitis differed 
among the groups. Pleuritis was only observed in pigs from the challenged groups. 
The most cases of severe pleuritis were seen in pigs from the tulathromycin 4 day 
followed by pigs from the nontreated-challenged and the tulathromycin 7 day groups. 
In contrast to pigs from the nontreated-challenged group, the most cases of severe 
pericarditis were seen pigs from both tulathromycin groups. In contrast to the pleuritis 
and pericarditis, peritonitis was observed in pigs from all study groups. Two pigs from 
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the control group had a mild peritonitis, and all the pigs from the tulathromycin 4 day 
group had some degree of peritonitis in contrast to pigs from the nontreated-
challenged and tulathromycin 7 day groups. However, statistical analysis 
demonstrated that the control pigs had significantly fewer cases of peritonitis in 
comparison to challenged pigs. Since the control pigs were not infected with HPS 
and HPS was not detected in any samples from these animals at any time during the 
study, it is assumed that the peritonitis was caused by another pathogen for example 
Escherichia coli. Escherichia coli is not only a commensal of the digestive tract of 
pigs but also responsible for manifestations such peritonitis (MEYER et al., 1971). 
Since pleuritis, pericarditis and peritonitis were observed in both the nontreated-
challenged pigs and the tulathromycin pigs, a significant antimicrobial effect of 
tulathromycin was not established. Detailed studies about the efficacy of 
tulathromycin and its effectiveness at lessening gross lesions such as pleuritis, 
pericarditis and peritonitis are currently unavailable. This is the first description about 
the association of such lesions and the efficacy of tulathromycin. Further 
examinations are necessary to confirm the results observed in this study. 
5.4 Histopathological lesions 
After histopathological examination, synovitis, pyelitis and meningitis were observed 
predominantly in tissue samples from challenged pigs which died prior to study 
termination. Pyelitis was the most frequent inflammation type found and it occurred 
either alone or together with a meningitis or synovitis. Although both meningitis and 
synovitis were observed, meningitis always occurred together with a pyelitis, synovitis 
or both. In an experimental study to identify lesions and colonization locations of 
HPS, VAHLE et al. (1995) found fibrinopurulent synovitis in challenged pigs. 
Numerous studies confirm the findings of meningitis in pigs infected with HPS 
(AMANO et al., 1994; BLANCO et al., 2004; MACINNES and DESROSIERS, 1999; 
PALZER et al., 2006a; SOLANO-AGUILAR et al., 1999). Only a few studies 
described finding kidney lesions to varying degrees. DE LA FUENTE et al. (2008a) 
described a few cases of necrosis of the renal tubules including calcification and non-
purulent interstitial nephritis in HPS infected pigs. Likewise, SOLANO et al. (1999) 
described the finding of fibrin deposits in the renal glomeruli of one pig experimentally 
infected with HPS serovar 5. In a field infection of weaned piglets in Australia, PEET 
et al. (1983) found kidney lesions in four pigs which were characterized by glomerular 
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thrombosis. Although the pigs in these studies demonstrated kidney lesions, pyelitis 
was never observed. This is the first study which describes a pyelitis in an HPS 
infected pig and further studies are necessary to confirm these observations. 
Despite tulathromycin application, a significant difference in the occurrence of the 
individual inflammations between the nontreated-challenged group and pigs from the 
tulathromycin groups was not observed. As mentioned previously in section 5.3.5, 
detailed study results about the efficacy of tulathromycin and its antimicrobial efficacy 
at preventing gross or histopathological lesions do not exist. This is the first 
description about the association of such lesions and tulathromycin efficacy and 
further studies are necessary to confirm the finding of these studies. 
5.5 Detection of HPS by PCR and bacterial culture 
HPS could be detected by PCR and bacterial culture in sample materials from at 
least 18 challenged pigs. HPS genome was detected in at least one of five sample 
materials from pigs of all three challenged groups, and HPS was reisolated in 10 
collective serosal swabs of pigs from all three challenged groups. As expected, HPS 
was not detected by PCR or culture in samples from the control pigs. Although a 
significant difference among the sample materials for HPS genome was not 
established in this study, HPS genome was most frequently detected in the collective 
serosal swabs and cerebrospinal fluids. This detection frequency corresponds to 
findings by PALZER et al. (2006c). ANGEN et al. (2007) noted that swabs were 
successfully used for sampling diseased animals for HPS diagnosis particularly by 
PCR. Furthermore, swabs allow easier handling and transportation compared to 
tissue samples. BLANCO et al. (2008) reported that the best chances for HPS 
detection by either PCR or bacterial culture are achieved when a combination of 
samples from the meninges, peritoneum and pleura were used. Likewise, OLIVEIRA 
et al. (2004) noted that ideal sites for isolation are the brain (meninges) pericardium, 
pleura, peritoneum, and joints. All of these recommended sampling sites were 
sampled when the five sample materials were used in this study. 
Although HPS was detected in samples from nontreated-challenged pigs and 
tulathromycin pigs, a significant difference of HPS detection among the challenged 
groups was not observed. These results demonstrate that HPS detection is possible 
despite previous antibiotic treatment. Similar results were observed by HAEDKE 
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(2008) for the detection of HPS genome by PCR in collective serosal swabs from 
pigs treated with antibiotics. 
After PCR detection, HPS was detected in the synovial samples from animals which 
died at study termination. Notably, HPS was not detected in the corresponding joint 
capsules. Similarly, HPS was detected predominantly in joint capsules from animals 
which died prior to study termination while the corresponding synovial fluids were 
negative for HPS genome. Therefore, at no point in this study, a corresponding 
identification of HPS genome in both synovial fluid and joint capsules was observed. 
Differences in the detection frequency of HPS may be due to different amount of the 
bacterium present in the synovial fluid and joint capsules. OLIVEIRA et al. (2001a) 
reported that the PCR required a minimum of 100 CFU ml-1 for detection. Another 
explanation may be that the bacterium is first localized in the joint capsule during the 
early stages of infection and in later stages of infection only in the synovial fluid. This 
is assumed since HPS was only detected in synovial fluids from animal which died at 
study termination. It is possible that different results may have been obtained if 
sample material from different joints including the right tarsal joint were used since 
only sample material from the left tarsal joint was used for PCR diagnostic. Further 
examinations are necessary to understand the mechanism of HPS colonization in the 
joint. 
5.6 Comparison of HPS detection by PCR and bacterial culture in 
collective serosal swabs from challenged pigs 
HPS genome was detected by PCR in twelve collective serosal swabs from 
challenged pigs. In contrast, HPS was only detected after bacterial culture in 
collective serosal swabs from 10 challenged pigs which died prior to study 
termination. A corresponding identification of HPS by both PCR and bacterial 
samples was seen for 10 samples. Although a significant difference between the 
successful detection of HPS was not established among both detection methods, 
HPS was more frequently detected by PCR testing than bacterial culture. Similarly, 
OLIVEIRA et al. (2006) found that PCR is a far more sensitive method for HPS 
detection in comparison to bacterial culture. According to RAPP-GABRIELSON et al. 
(2006) PCR is useful for diagnosis when bacterial isolation is negative. Conversely, 
TURNI and BLACKALL (2007) found that the PCR did not perform as well as culture 
due to the low amount of HPS present in samples. Likewise, BLANCO et al. (2008) 
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found that HPS isolation was more successful after using bacterial culture than PCR. 
However, this author noted that PCR is still an appropriate tool for detection of HPS 
since bacterial isolation is limited due to the fastidious nature of the bacterium. 
Furthermore the same author reported that bacterial isolation is not always possible 
when samples are isolated form dead pigs due to the possible contamination by 
other bacteria. 
5.7 Associations between HPS detection, the clinical results and 
pathological lesions 
5.7.1 Association between HPS detection and clinical results 
After HPS challenge on Day 0, mild to severe clinical signs associated with Glässer’s 
disease were seen in all challenged animals. Moreover, 12 pigs from all three 
challenge groups died within ten days post challenge as a result of their severe 
clinical symptoms. HPS genome was detected in sample materials from 9 animals 
which were clinically sick and in all sample materials from animals which died prior to 
study termination. HPS genome was also detected in a total of 6 sample materials 
from pigs which died at study termination and in sample materials from 3 animals 
which were clinically healthy. It is possible that given more time, those pigs could 
have developed more obvious lesions, or perhaps the immune system of the pig was 
able to control bacterial growth and prevent the lesions from developing in those 
tissues. Similarly, HPS was isolated by bacterial culture in sample materials from 8 
animals which were clinically sick and in 10 animals which died prior to study 
termination. Based on these results, a significant association between HPS detection 
by PCR or bacterial culture and sample materials which came from animals with 
clinical signs and from animals that died prior to study termination was established. 
This finding is consistent with the results from HAEDKE (2008) and PALZER et al. 
(2006b). OLIVEIRA (2004) observed successful HPS detection when animals with 
clinical signs of HPS infection are used. The same author also noted that isolation 
from chronically affected pigs is usually unsuccessful. TURNI and BLACKALL (2007) 
found more frequent HPS detection in sample materials from animals which were 
euthanized in comparison to animals which only showed mild clinical signs. In one of 
the first studies on HPS detection, HPS was readily recovered from pigs in the acute 
stages of experimental infection, but was isolated only sporadically from pigs with 
lameness at later time (NEIL et al., 1969).  
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As mentioned previously in section 5.5, HPS synovial fluids were only positive in 
samples from animals that died at study termination. Notably, HPS genome was not 
identified in the corresponding joint capsules. The joint capsules and cerebrospinal 
fluids were the only sample materials which successfully identified HPS genome in 
samples from animals that died both prior to and at study termination. However, HPS 
genome could not be detected in the corresponding synovial fluids of these animals. 
An explanation for these observations could be that the bacterium is first localized in 
the joint capsule at the early stages of infection and in later stages of infection only in 
the synovial fluid. Notably, only samples from the left tarsal joint were used for HPS 
diagnostic. Further examination is necessary to see if a similar detection pattern 
exists for samples from other joints. 
5.7.2 Association between HPS detection and pathological lesions 
Gross and histological lesions characteristic of Glässer’s disease were seen in 
several pigs from all three challenged groups. Polyserositis was found in 17 pigs from 
three challenged groups. Findings of inflammations of the serosal membranes with 
fibrinous to fibrinopurulent exudates is a characteristic feature of an acute HPS 
infection (OLIVEIRA and PIJOAN, 2002). In this study, HPS was detected 
significantly more frequently by PCR and bacterial culture in collective serosal swabs 
from animals with a polyserositis than animals without a polyserositis. These results 
are consistent with the findings of HAEDKE (2008) who also found a significant 
association between the detection of HPS in collective serosal swabs and 
polyserositis. In one case, HPS was detected although a polyserositis was not 
present. According to PALZER et al. (2006c), the detection of HPS genome in 
collective serosal swabs from animals without pathological lesions are possibly due 
to the fact that an early stage of infection is present. 
By the differentiation between inflammations of the pleura, pericardium and 
peritoneum, significant associations were not observed in all cases. HPS was 
detected significantly more frequently in samples from animals with a pleuritis and 
peritonitis. Similar observations were made by HAEDKE (2008) who found a 
significant association between the detection of HPS genome and pleuritis and 
pericarditis. HPS could be detected in samples from pigs with and without pericarditis 
but a significant association between HPS detection and pericarditis was not 
established. In this case, as previously mentioned, the possibility of HPS detection 
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without pathological lesions due to an early infection stage needs to be taken into 
consideration (PALZER et al., 2006c). 
Although HPS genome was found in the brain, synovial and cerebrospinal fluids of 
animals with and without meningitis and synovitis, a significant association between 
HPS detection and these gross and histopathological lesions was not observed in 
this study. HADEKE (2008) also did not find a significant association between the 
detection of HPS genome and changes in the joint. In contrast, PALZER et al. 
(2006c) found an association between the detection of HPS genome from collective 
serosal swabs and pathologically changed joints. As mentioned previously, the fact 
that sample materials for the HPS genome detection were only obtained from the left 
tarsal joint, it is possible that differing results may have been observed if samples 
from other joints were also used for diagnostic in this study. 
SOLANO et al. (1997) and VAHLE et al. (1995) found that cerebrospinal fluid was an 
excellent material for isolation of the bacteria when animals showed central nervous 
signs. It is possible that the bacterium was present in the respective tissue and fluids 
but it was not in sufficient amounts to be detected by this HPS PCR. The dynamics of 
how the bacterium interacts with joint tissues and meninges remains to be 
determined (BLANCO et al., 2008). 
One notable discovery after histopathological examination was the pyelitis 
occurrence in 10 challenged pigs. HPS genome was detected significantly in sample 
materials from 10 of these pigs and in collective serosal swabs of 8 pigs with pyelitis. 
HPS was detected by both PCR and bacterial culture in samples from two pigs 
without a pyelitis. As previously mentioned, the bacteria was probably present in the 
tissue and given more time, maybe corresponding histopathological lesions would 
have appeared. Histopathological examinations of pigs from some previous studies 
indicated kidney and pelvis lesions after HPS infection (DE LA FUENTE et al., 
2008a; PEET et al., 1983; SOLANO et al., 1997). Pyelitis has never been mentioned 
in these studies or any other publications as a lesion of HPS infection. Furthermore, 
a correlation between the occurrence of pyelitis or kidney and pelvis lesions and the 
detection of HPS has never been determined. This study found that HPS was more 
frequently detected in samples from animals with a pyelitis than animals without a 
pyelitis. These results are being reported for the first time and further studies are 
necessary to confirm these results. 
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5.8 Conclusion 
The aim of this study was to evaluate the efficacy the two different tulathromycin 
treatments administered as a single dose prior to an intratracheally challenge with 
HPS serovar 5 in 36 weaned piglets. The efficacy the two tulathromycin treatments 
was evaluated based on parameters such as mortalities, the results from the clinical 
examinations and pathological lesions. 
The HPS challenge model produced peracute, severe clinical signs which resulted in 
the death or euthanasia of four pigs from all three challenged groups within ten days 
post infection. A significant difference among the challenged groups was not 
observed. Likewise, the average daily weight gains (ADG) and rectal temperatures of 
tulathromycin-treated animals did not differ significantly from the nontreated-
challenged pigs. Furthermore, a significant difference among the leukocyte 
population of the pigs was only observed between the control pigs and the 
challenged pigs. Typical gross and histopatholgical lesions of Glässer’s disease such 
as pleuritis, pericarditis, peritonitis, meningitis, and synovitis were observed after 
necropsy. But a significant difference among the challenged groups was not seen. In 
addition to these lesions, pyelitis was identified in seven challenged pigs. This is the 
first study which reports the findings of these lesions in HPS infected pigs and further 
studies are necessary to confirm these observations. 
The fact that clinical signs, gross and histopathological lesions indicative of Glässer’s 
disease were observed after intratracheal challenge with HPS serovar 5, confirms the 
success of this infection model. However, according to the efficacy evaluation 
parameters of this study, the administration of tulathromycin 4 and 7 days prior to an 
infection with HPS serovar 5 did not appear to have a significant antimicrobial effect 
against the infection dose used in this study. This may have been due to the 
challenge model setup. For example, the challenge inoculum dose may have been 
too high or the inoculation route used in the study was inappropriate. Intratracheal 
administration has the advantage of overcoming the mucosal defense thus facilitating 
systemic infection more easily. Other routes such as intranasal infection should be 
taken into consideration since it represents the most natural route of HPS infection. 
Further studies examining the efficacy of tulathromycin taking these changes into 
consideration are necessary.  
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In addition to clinical and pathological evaluation, associations between the 
frequency of HPS detection by PCR and bacterial culture and the results from the 
clinical and pathological parameters were assessed. HPS was significantly detected 
by PCR and bacterial culture in samples from animals with clinical symptoms and 
animals which died acutely prior to study termination. Furthermore, a significant 
association between the detection of HPS and sample materials from animals with 
pleuritis, peritonitis, meningitis and pyelitis was established. Bacterial isolation of 
HPS was only successful in collective serosal swabs from animals which died prior to 
study termination. HPS genome was detected by PCR in all five sample materials but 
the most successful detection was seen after the testing of the collective serosal 
swabs and cerebrospinal fluids. Notably, HPS genome was only detected in synovial 
fluids from animals which died at study termination, while the corresponding joint 
capsules were negative for HPS genome. Similarly, HPS was detected 
predominantly in joint capsules from animals which died prior to study termination but 
the corresponding synovial fluids were negative for HPS genome. Further 
investigations are necessary to confirm the HPS detection results observed by the 
synovial fluids and joint capsules since PCR testing was only performed on sample 
materials from the left tarsal joint. Moreover, studies are required to examine the 
relationship between gross lesions such as pyelitis and the detection of HPS. 
Notwithstanding these facts, the detection results demonstrate that the PCR and 
bacterial examination of various sample materials is a suitable diagnostic tool to 
detect all stages of HPS infection, even in animals treated with antibiotics. 
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6 Summary 
Once viewed as an infrequent disease of young pigs, Glässer’s disease has emerged 
as a major pathogen affecting naïve swine herds (BLANCO et al., 2008). This 
disease is characterized by polyserositis, arthritis and meningitis in swine 
(RITZMANN and HEINRITZI, 2005). Due to the genetic diversity of Haemophilus 
parasuis (HPS), the etiological agent of Glässer’s disease, vaccine regimes are not 
always effective and prudent use of antimicrobials is considered an important 
component in controlling the disease. The aim of this study was to evaluate the 
efficacy of two different tulathromycin treatments (Draxxin®, Pfizer, GmbH, Berlin) 
administered as a single dose prior to an intratracheally infection with HPS serovar 5 
in weaned piglets. The efficacy of the two tulathromycin treatments was evaluated 
based on mortalities and the results from the clinical examinations and pathological 
lesions.  
Thirty-six piglets, 3 weeks of age, were obtained from a commercial nursery site with 
no previous history of porcine reproductive and respiratory syndrome virus (PRRSV), 
Mycoplasma hyopneumoniae or HPS. Antibodies for Actinobacillus 
pleuropneumoniae were also not detected in blood samples from the study pigs. 
After arrival at the biosafety level 3 facility of the Clinic for Swine, Veterinary 
University Vienna Austria on study day -17, piglets were housed in separate units 
and assigned to four study groups: control, nontreated-challenged, tulathromycin 
4 day pretreated-challenged, and tulathromycin 7 day pretreated-challenged. All 
piglets were allowed a 10-day acclimatization period before piglets of the 
tulathromycin-7-day group received the registered dose of 2.5 mg/kg BW 
tulathromycin intramuscularly on study day -7. Three days later (Day -4) piglets from 
the tulathromycin-4-day group were also administered 2.5 mg/kg BW tulathromycin 
per intramuscular injection. With the exception of pigs from the control group, all pigs 
were administered 5 ml of 5 x 108 CFU HPS serovar 5 intratracheally on study day 0. 
Pigs from the control group received phosphate-bufferedsaline (PBS) instead. 
Clinical examinations of all pigs occurred at least once daily until study termination on 
Days 14 and 15. Furthermore, necropsy and histopathological examination was 
performed at study termination or prior to study termination if a pig died or was 
euthanized due to severe clinical symptoms. In addition to these examinations, 
synovial fluid, cerebrospinal fluid, joint capsules and brain swabs (meninges) were 
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collected from all animals for PCR. Collective serosal swabs from all 36 piglets were 
also tested for HPS by PCR and bacterial culture.  
After challenge, severe clinical signs indicative of Glässer’s disease were seen in 
pigs from all three challenged groups, and 44 % of the challenged pig (4 pigss from 
each challenged group) died within ten days post infection. Significant differences 
between the nontreated-challenged group and pigs which were administered 
tulathromycin for these observations were not established. Rectal temperatures and 
average daily weight gains (ADGs) of tulathromycin-treated animals did not differ 
significantly from those of the nontreated-challenged pigs. Gross and 
histopathological lesions of Glässer’s disease were seen in pigs from all three 
challenged groups but a significant difference among these groups was not found. 
Furthermore, pyelitis was observed in seven challenged pigs. This is the first study 
which reports the findings of these lesions in HPS infected pigs and further studies 
are required to confirm these findings. HPS was significantly more frequently 
detected by PCR and bacterial culture in sample materials from animals which had 
clinical symptoms and animals which died prior to study termination in comparison to 
animals which died at study termination and which were clinically healthy. 
Furthermore, HPS was significantly more frequently detected by PCR and bacterial 
culture in sample materials from animals with gross lesions such as pleuritis, 
pericarditis, peritonitis and pyelitis than swabs from animals without such lesions. 
In conclusion, based on the results of the clinical examinations, gross and 
histopathological lesions, the administration of tulathromycin 4 and 7 days prior to the 
experimental HPS infection did not appear to have a significant antimicrobial effect 
against the infection dose and serovar used in this study. Reasons for this finding are 
most likely due to the challenge model used in this study. Factors such as unsuitable 
application times may have contributed to these findings. Furthermore, the challenge 
inoculum dose may have been too high or the inoculation route used in the study was 
inappropriate. Further studies examining the efficacy of tulathromycin taking these 
changes into consideration are necessary. The results from this study confirm the 
PCR testing and bacterial culture of various sample materials as suitable diagnostic 
tools for all stages of HPS infection, even in animals treated with antibiotics prior to 
testing. 
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7 Zusammenfassung 
Beurteilung der Wirksamkeit von zwei unterschiedlichen Tulathromycin- 
Behandlungen bei intratracheal mit Haemophilus parasuis Serovar 5 infizierten 
Absetzferkeln  
 
Während die Glässer’sche Krankheit früher als eine sporadische Erkrankung bei 
jungen Schweinen galt, hat sie sich inzwischen zu einer bedeutenden Erkrankung in 
naiven Schweineherden entwickelt (BLANCO et al., 2008). Wegen der genetischen 
Vielfalt von Haemophilus parasuis (HPS), dem Erreger der Glässer’schen Krankheit, 
sind Impfprogramme nicht immer effektiv, und eine gezielte Antibiotikatherapie ist 
häufig erforderlich, um die Krankheitssymptome zu kontrollieren. Ziel dieser Studie 
war es, die Wirksamkeit von zwei unterschiedlichen, einmaligen Behandlungen mit 
Tulathromycin (Draxxin®, Pfizer, USA) vor einer intratrachealen Infektion mit HPS von 
Absetzferkeln zu evaluieren. Die Wirksamkeit wurde anhand der Mortalitätsraten, der 
Ergebnisse der klinischen Untersuchungen sowie der pathomorphologischen und 
pathohistologischen Untersuchungen evaluiert. 
Die 36 Ferkel für diese Studie stammten aus einem Ferkelproduktionsbetrieb, der frei 
ist von Porcinem Respiratorischen und Reproduktiven Syndrom-Virus (PRRSV), 
Mycoplasma hyopneumoniae und HPS. Die Tiere waren zum Zeitpunkt des 
Einschlusses drei Wochen alt und wurden in vier Gruppen eingeteilt: eine 
Kontrollgruppe, eine unbehandelt-infizierte Gruppe, eine Gruppe, die am vierten Tag 
vor der Infektion mit Tulathromycin behandelt wurde (4-Tage-Tulathromycin-infiziert), 
sowie eine Gruppe, die am siebten Tag vor der Infektion mit Tulathromycin behandelt 
wurde (7-Tage-Tulathromycin-infiziert). Schweine der 7-Tage-Tulathomycin-Gruppe 
und der 4-Tage-Tulathromycin-Gruppe bekamen am Studientag -7 bzw. -4 die 
zugelassene Dosis von 2,5 mg/kg Körpergewicht Tulathromycin intramuskulär 
appliziert. Am Studientag 0 wurde allen Schweinen, mit Ausnahme der Tiere der 
Kontrollgruppe, 5 ml einer Suspension aus HPS Serovar 5 (5 x 108 CFU) 
intratracheal appliziert. Die Tiere wurden während des gesamten Studienverlaufes 
mindestens einmal täglich klinisch untersucht. Eine pathologische Untersuchung 
wurde am letzten Studientag oder bei Tieren mit schwerwiegenden klinischen 
Symptomen am Tag der Tötung bzw. des Verendens durchgeführt. Im Rahmen der 
Sektion wurden von allen Tieren Synovia, Liquor, Gelenkkapsel und 
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Gehirntupferproben für eine Untersuchung mittels PCR entnommen. Weiters wurden 
Serosensammeltupfer von allen 36 Studientieren mittels PCR und Kulturversuch auf 
HPS untersucht. 
Charakteristische Symptome der Glässer’schen Krankheit konnten nach der Infektion 
bei Tieren aller drei infizierten Gruppen beobachtet werden. Vier Tiere aus jeder 
infizierten Gruppe verendeten innerhalb von zehn Tagen nach der Infektion. Es 
konnten keine signifikanten Unterschiede zwischen der unbehandelt-infizierten 
Gruppe und den Tulathromycin-behandelten Gruppen festgestellt werden. Es 
konnten sowohl in der pathomorphologischen als auch in der pathohistologischen 
Untersuchung Veränderungen beobachtet werden, die für die Glässer’sche Krankheit 
charakteristisch sind. Es gab jedoch keine signifikanten Unterschiede zwischen 
diesen Gruppen. Darüber hinaus wurde bei sieben der infizierten Tiere eine Pyelitis 
diagnostiziert. Da in dieser Studie erstmalig solche Veränderungen bei mit HPS 
infizierten Schweinen beschrieben wurden, sind weitere Untersuchungen nötig, um 
dies zu bestätigen. Es konnte signifikant häufiger HPS mittels PCR und 
bakteriologischer Untersuchung bei Tieren nachgewiesen werden, die klinische 
Symptome zeigten oder vor Studienende verstarben. Des Weiteren konnte HPS 
signifikant häufiger in Probenmaterialien von Tieren nachgewiesen werden, die 
pathologische Veränderungen wie Pleuritis, Peritonitis und Pyelitis zeigten. 
Aufgrund der Ergebnisse der klinischen Untersuchung, sowie der 
pathomorphologischen und pathohistologischen Veränderungen scheint die 
Applikation von Tulathromycin vier bzw. sieben Tage vor der experimentelle Infektion 
mit HPS keine ausreichende antibakterielle Wirksamkeit bei der verwendeten 
Infektionsdosis und dem verwendeten Isolat gezeigt zu haben. Dies ist 
wahrscheinlich im Versuchsaufbau dieser Studie begründet, die verwendete  
Infektionsdosis war entweder zu hoch oder der verwendete intratracheale 
Infektionsweg ungeeignet. Andere Faktoren, wie zum Beispiel die ungeeigneten 
Applikationszeitpunk von Tulathromycin könnten ebenso zu diesen Resultaten 
führen. Um dies zu verifizieren/falsifizieren sind Folgestudien, die die Wirksamkeit 
von Tulathromycin weiter untersuchen, notwendig.  
Die Ergebnisse dieser Studie bestätigen, dass die Untersuchung von verschiedenen 
Probenmaterialien mittels PCR und Kulturversuch sowohl bei mit Antibiotika 
vorbehandelten als auch bei unbehandelten Tieren geeignet ist, um eine HPS 
Infektionen nachzuweisen.  
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